

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

NANOPIERCE TECHNOLOGIES INC
Form 10KSB
October 05, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-KSB

(Mark one)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

FOR THE FISCAL YEAR ENDED: JUNE 30, 2005

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

Commission file number: 33-19598-D

NANOPIERCE TECHNOLOGIES, INC.

Exact name of registrant as specified in
its charter

Nevada

84-0992908

(State of other jurisdiction of
incorporation or organization)

(I.R.S. employer
identification number)

370 Seventeenth Street, Suite 3640
Denver, Colorado 80202

(Address and zip code of principal executive office)

(Former address of principal executive office)

Registrant's telephone number, including area code: (303) 592-1010

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: None

(Title of Class)

Name of Each
Exchange On Which
Registered

Common Stock,
0.0001 Par Value

NASDAQ:BB
Frankfurt Exchange
Hamburg Exchange

Indicate by check mark whether the registrant: (1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934, during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes No

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-B is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statement incorporated by reference in Part III or this Form 10-KSB or any amendment hereto. [X]

As of the close of trading on October 3, 2005, there were 133,059,033 shares outstanding, 130,996,765 of which were held by non-affiliates. The aggregate market value of the common shares held by non-affiliates, based on the average closing bid and asked prices on October 3, 2005, was approximately \$10,938,230.

The registrant's revenue for the fiscal year ended June 30, 2005 was \$0.

Transitional Small Business Disclosure	Yes	No	X
	-----	-----	

PART I

ITEM 1. DESCRIPTION OF BUSINESS

COMPANY OVERVIEW

NanoPierce Technologies, Inc. (the "Company") is a Nevada corporation that was incorporated on June 22, 1996, as Sunlight Systems, Ltd. From June 22, 1996 through November 1996 the Company engaged in limited activities as a dealer and distributor of sun tunnels. This business, however, was discontinued and substantially all assets were sold in November of 1996. From that time until February 1998, the Company was generally inactive and reported no significant operating revenues.

On February 26, 1998, the Company acquired the intellectual property rights related to the Company's patented Particle Interconnect Technology (the "PI Technology") from Particle Interconnect Corporation ("PI Corp"), a Colorado corporation, and a wholly owned subsidiary of Intercell Corporation (now known as Intercell International Corporation, hereinafter "Intercell"), a Nevada corporation.

The Company acquired the PI Technology in order to pursue a more focused, strategic application and development of the PI Technology, subsequently referred to as the NanoPierce Connection System ("NCS(TM)"). NCS is an alternative method of providing temporary or permanent electrical connections between different flexible, rigid, metallic and non-metallic surfaces. Through the use of the particle technology, the Company can also attach semi-conductors directly to various surfaces. The Company has trademarked this process as WaferPierce(TM).

The Company does not plan, at this time, to continue efforts to manufacture or develop products that utilize the Company's PI Technology. To date, the Company has not successfully manufactured, marketed, sold products or licensed companies to manufacture, develop and market products using the Company's PI Technology.

TECHNOLOGY PLATFORM CHANGE

Beginning in October 2004, the Company instituted steps to change its technology platform from a semiconductor based technology platform to a biotechnology based platform. The formal change occurred on August 15, 2005,

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

when the Company purchased a 50% interest in BioAgra, LLC ("BioAgra"), a limited liability company, organized under the laws of the State of Georgia.

CORPORATE RESTRUCTURING

Management of the Company has been authorized by the Board of Directors to institute a plan for corporate restructuring. This plan includes (i) the creation of a class of convertible preferred shares with super voting power; (ii) the issuance of a subscription agreement for the convertible preferred shares; (iii) a reverse stock split and a record date for such stock split to be determined in the near future; (iv) an increase in authorized common shares post-reverse split; and (v) a change of the name of the Company.

1

On September 26, 2005, the Company executed a Subscription Agreement to sell the Company's Preferred Stock to Arizcan Properties, Ltd. ("Arizcan Properties"). The Subscription Agreement provides for the purchase of 200,000 shares of a Class A 8% cumulative and participating preferred shares with a sales price of \$7.50 per share. The preferred shares are convertible into 60% of the Company's issued and outstanding post-split shares of its common stock on the date of conversion.

SUBSIDIARIES AND INVESTMENTS

BIOAGRA, LLC ("BIOAGRA"). In August 2005, the Company purchased a 50% equity interest in BioAgra, a Georgia limited liability company for approximately \$905,000 in cash and a note payable of \$595,000, which was paid in full on September 15, 2005. BioAgra is located in Hinesville, Georgia. The remaining 50% was purchased by Xact Resources International for the contribution of rights, a license, intellectual properties, purchase orders and similar items. The Company does not have a controlling interest on BioAgra. BioAgra holds a license for the production of YBG-2000. The license, dated April 18, 2005, has a term expiring October 18, 2024. YBG-2000 is a natural beta glucan feed additive used to replace artificial antibiotics, currently in use. Under the license BioAgra has an exclusive right to manufacture and sell the licensed products in the United States and a non-exclusive right to sell throughout the rest of the world. BioAgra plans to manufacture and market YBG-2000, initially for sale in the poultry industry, starting in January 2006.

Currently, BioAgra is in the process of constructing the production line. BioAgra expects to begin producing and shipping product at the beginning of 2006. As the production line is being completed, management of BioAgra is developing marketing plans for the sale and distribution of the product, marketing strategies and hiring administrative and manufacturing staff.

NANOPIERCE CARD TECHNOLOGIES, GMBH ("NANOPIERCE CARD"). Established in January 2000, NanoPierce Card was located in Hohenbrunn, Germany. NanoPierce Card was responsible for the marketing of the Company's technology, services and products on an international basis. On April 1, 2003, NanoPierce Card filed for insolvency with the Courts of Munich, Germany. The insolvency was necessary in order to comply with specific German legal requirements. The Company completed a plan of self-liquidation and the German court legally dissolved NanoPierce Card on June 8, 2004.

NANOPIERCE CONNECTION SYSTEMS, INC. ("NANOPIERCE CONNECTION"). NanoPierce Connection, a Nevada corporation, was located in Colorado Springs, Colorado, USA. Beginning business in January 2002, NanoPierce Connection was the center for research and development activities. In September 2003, the Company entered into a joint venture with Scimaxx, LLC in order to further the marketing of the services previously offered by NanoPierce Connection. During the fiscal year

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

ended June 30, 2005, NanoPierce Connection had no operations.

2

EXYPNOTECH, GMBH ("EXYPNOTECH"). ExypnoTech was organized in February 2002. ExypnoTech produces inlay components used in the manufacturing of, among other things, smart labels (often referred to as radio frequency identification tags or "RFID"). ExypnoTech, in addition to the inlay components, plans to manufacture and sell other types of RFID components. In December 2003 ExypnoTech sold a controlling 51% interest in ExypnoTech to TagStar Systems, GmbH for \$98,000 in cash. As a result of this sale, the Company does not have a controlling interest in ExypnoTech and the Company is only entitled to 49% of the net income generated by ExypnoTech if any, and shares in 49% of any net losses. ExypnoTech, if able, will pay dividends on an annual basis. The Company is entitled to 49% of the dividends, if any, paid as a result of any future profits of ExypnoTech.

SCIMAXX SOLUTIONS, LLC ("SCIMAXX SOLUTIONS"). On September 15, 2003, the Company entered into a joint venture with Scimaxx, LLC (Dr. Neuhaus, a director of the Company is a part owner of Scimaxx, LLC - See Item 12). In April 2005, Scimaxx Solutions, LLC discontinued operations. The purpose of the joint venture was to provide the electronics industry with technical solutions to manufacturing problems based on the need for electrical connectivity. The Company received a 50% interest in the joint venture in exchange for a contribution of the equipment owned by NanoPierce Connection. The Company also granted Scimaxx Solutions a ten-year, non-exclusive, non-royalty bearing worldwide license to use the Company's intellectual property. The Company and Scimaxx, LLC intend to formerly terminate Scimaxx Solutions in the near future, at which time the license will terminate.

EXYPNOTECH, LLC ("EXYPNOTECH, LLC"). On June 18, 2004, the Company organized ExypnoTech, LLC as a wholly-owned subsidiary to market, primarily in the United States of America, the RFID components manufactured by ExypnoTech, GmbH. During the last 6-months of the fiscal year ended June 30, 2005, ExypnoTech, LLC did not have active operations.

THE NCS(TM) TECHNOLOGY

NCS(TM) is a method where metallized, hard, microscopic particles are deposited onto one of two contact surfaces, through electrolytic or electro-less plating methods or other methods. When the two surfaces are pressed together, the conductive particles penetrate the second contact surface and create an electrical connection. Bonding of the contact surfaces can be achieved using nonconductive adhesives or ultrasonic welding.

NCS can be used with many different substrates (flexible, rigid, metallic and non-metallic), allowing NCS to replace more conventional methods of making electrical contacts, such as soldering, spring-loading, pin-in-hole connections and conventional "flip chip" attachment. In addition, NCS can be used to form either temporary or permanent connections.

NCS provides advantages to potential users among which are; lower costs through the usage of less expensive materials; the elimination of manufacturing steps; improved thermal and electrical properties; elimination of special environments for application; decreased production time; easy integration into existing production lines; increased design miniaturization; adaptability for specific applications and RF (radio frequency) performance.

3

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

The Company has extended NCS to permit the direct attachment of semiconductor chips to a substrate, a process called WaferPierce(TM). WaferPierce is comprised of two parts: (1) the electroless application of NCS to the contact pads of chips while still in wafer form; and (2) a proprietary chip attachment process in which chips are bonded to a substrate face down using the core NCS method.

The Company currently holds 13 Patents with the U.S. Patent and Trademark Office. Further, the Company has filed several patent applications both in the United States and internationally in order to continue to protect its intellectual property. To reduce expenses, during the fiscal years ended June 30, 2005 and 2004, the Company abandoned several of its patent applications. The Company also holds several trademarks with the U.S. Patent and Trademark Office, in connection with the Company's name, logo and services.

BUSINESS STRATEGY

The Company, through its investment in ExypnoTech and joint venture, BioAgra, is targeting the following business activities:

1. RFID COMPONENTS. RFID components are used to identify objects, by short-range radio over a few millimeters to distances as great as a meter. RFID inlays consist of a small transponder chip bonded onto a metal foil antenna on an exceptionally thin and small plastic or paper sheet. NCS can be used to provide the connection between the transponder chip and the antenna. In addition, NCS can be used to connect the chip to the chip module in contact smart cards or the chip module to the antenna in the case of contactless smart cards. There are many different applications for RFID components, but the application being focused on by the Company is smart labels. ExypnoTech currently offers RFID components using the Company's intellectual property.
2. BETA GLUCAN ADDITIVE. YBG-2000 is a beta glucan feed additive produced from spent brewer's or baker's yeast. The additive is a combination of bioactive nutrients and B-glucans that are extracted from the cell walls of the yeast using steam injection and a centrifuging extraction process. The beta glucan additive is an all natural, organic compound that has been proven to stimulate immune systems, thereby eliminating the usage of antibiotics and growth hormone supplements in animal, poultry and other feeds. YBG-2000 is designed to achieve two purposes. For example, in the poultry industry, the first is to enhance the avian immune system to fight bacterial and viral infections more effectively and efficiently, and secondly, to promote accelerated growth. Currently, animals in the cattle, poultry, swine and shrimp industries are fed artificial antibiotics, in order to prevent the spread of bacterial and viral infections and steroids to promote growth. BioAgra is initially targeting customers in the poultry processing industry.

Currently, governments are urging, if not, directing producers to remove artificial antibiotics from the human food chain supply to reduce the development in humans of increasingly powerful and virulent strains of antibiotic resistant bacteria, which makes treatment for illnesses and diseases more difficult and expensive. In addition, food service providers are demanding natural, organic, antibiotic free foods.

As previously mentioned, BioAgra is developing marketing plans and

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

strategies for YBG-2000 while the construction of the production line is being completed. The initial marketing strategy is to penetrate the poultry producing industry and to that extent, contact has been made with potential customers, though no formal contracts have been signed, at this point. Assuming BioAgra can successfully sell product to the poultry producing industry, BioAgra intends to market and sell to other industries such as the swine and shrimp processing industries.

RESEARCH AND DEVELOPMENT

The Company's research and development activities were formerly conducted through NanoPierce Connection, with additional activities occurring at ExypnoTech. During the last year, minimal research and development activities were conducted at Scimaxx Solutions. For the fiscal years ended June 30, 2005 and June 30, 2004, the Company incurred \$0 and \$41,849, respectively, in research and development expenses.

The Company does anticipate that a substantial level of research and development activities will occur at BioAgra.

COMPETITION

Competition in the electronic connector market is fierce. The principal competitive factors are product quality, performance, price and service. The Company and its licensees face competition from well-established firms with other interconnect technologies. The Company will face competition from the development of existing and future competing technologies. There currently exists approximately 28 different technologies that can be used to create interconnect solutions, including dendrite crystals, gold dot technology, anisotropic technology (technologies using materials whose behavior differs in the up/down and left/right directions), elastomerics (rubber-like synthetic materials) and Z-axis conductive adhesives. These technologies currently are produced by materials and chemical suppliers, flexible and rigid printed circuit board manufacturers, as well as electronics manufacturers who produce their own materials and interconnect systems.

Competition, at present, for beta glucan products in the market targeted by BioAgra is limited. The United States and many other countries in the world are in the process of eliminating or plan to eliminate the usage of antibiotics in the feed of animals in the human food chain supply. There are a limited number of alternatives to antibiotics. Such alternatives include organic acids, plant extracts (ex. oregano oil), and mannoproteins. These alternatives have not experienced a great success rate.

Other potential competitors include those already producing beta glucan for human consumption. This type of "purified" beta glucan is considered too expensive to use in markets other than for direct human consumption. Other competitors are those producing beta glucan with a 60% or less bioactivity level for the markets addressed by BioAgra. Based upon data provided to the Company beta glucan having less than 80% bioactivity is not effective in the markets chosen by BioAgra. BioAgra intends to produce an 80% pure beta glucan.

5

Competition will also consist of established producers of artificial antibiotic growth promotion products. These are large companies with vast resources allocated to the protection of the brand recognition and market share of their products.

SOURCES OF RAW MATERIALS

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Production of the beta glucan additive requires spent brewer's or baker's yeast. Brewer's yeast is used in the production of alcoholic beverages. Arrangements are being made with commercial firms that purchase and distribute these types of yeast. There is an adequate supply of these raw materials for the foreseeable future for BioAgra's activities.

CUSTOMERS

BioAgra is in the initial stages of marketing and contacting potential customers of its product, YBG-2000. Initial customers are expected to be poultry producers located in the United States and abroad.

GOVERNMENT REGULATION

The Company believes that it is in compliance with all federal and state laws and regulations governing its limited operations. Further, the Company believes that it is in compliance with all German laws and regulations governing its limited operations in Germany. Compliance with federal and state environmental laws and regulations did not have a material effect on the Company's capital expenditures, earnings or competitive position during the fiscal year ended June 30, 2005.

To the knowledge of the Company, the YBG-2000 beta glucan product planned to be produced by BioAgra is not subject to the regulations of either the U.S. Food and Drug Administration ("FDA") or U.S. Department of Agriculture ("USDA") because it is considered to satisfy the criteria set forth for products "generally regarded as safe" ("GRAS").

EMPLOYEES

On June 30, 2005, the Company and its subsidiaries had two employees. Mr. Metzinger and Ms. Kampmann, key officers of the Company and the only two employees of the Company, have signed employment agreements with the Company. (See- ITEM 9- "Directors and Officers of the Company") None of the Company's employees are represented by a labor union or are subject to a collective bargaining agreement. The Company believes that its relations with its employees are excellent.

As previously mentioned, BioAgra intends to hire administrative staff and production staff. It expects to have initially 12 production employees for a two-shift production cycle.

6

FACTORS AFFECTING FUTURE OPERATING RESULTS

Our future results may be affected by various risks and uncertainties including the following:

WE HAVE A HISTORY OF LOSSES

Developing our particle technology and its applications has been and we expect will continue to be expensive. Our operating expenses have consistently exceeded our revenues. We reported a net loss of \$997,616, \$1,558,083, and \$4,017,785 for the fiscal years ended June 30, 2005, 2004 and 2003, respectively.

WE MAY NOT BE ABLE TO CONTINUE AS A GOING CONCERN

Our independent auditors' report of our consolidated financial statements as of June 30, 2005, and for each of the years in the two year period then ended

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

includes an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. If we are unable to secure significant additional financing, we may be obligated to seek protection under the bankruptcy laws and our shareholders may lose their investment.

WE MAY BE UNABLE TO SUCCESSFULLY COMPETE IN THE MARKETPLACE

Our markets are highly competitive. Our success will depend in part on how quickly competitors can design and develop competing products and technologies. We are disadvantaged competing against these competitors in several different areas, including:

- financial resources;
- technological resources;
- manufacturing capabilities;
- diversity of revenue sources and business opportunities;
- personnel and human resources; and
- research and development capabilities.

Our larger competitors have long term advantages over us in research and new product development and have a greater ability to withstand periodic downturns in the market because they have diverse product lines that can provide revenue even when there is a downturn in the market.

WE CANNOT GUARANTEE THE QUALITY, PERFORMANCE OR RELIABILITY OF OUR PRODUCTS

We have no prior experience in taking technology to the manufacturing or production stage. We expect that the customers of our products will demand quality, performance and reliability.

7

THERE MAY BE INSUFFICIENT DEMAND FOR OUR TECHNOLOGY OR PRODUCT

We must convince our potential customers that our technology is technologically sound and can be manufactured efficiently and cost-effectively. To create consumer demand, we have to successfully market and sell our technology and products. Even after these efforts, our technology and products may not be viewed by consumers as an improvement over existing technologies and products and may not achieve commercial acceptance.

WE MAY BE UNABLE TO MEET OUR ONGOING NEEDS FOR ADDITIONAL CAPITAL

We cannot accurately predict how much funding we will need to implement our strategic business plan or to continue operations. Our future capital requirements, the likelihood that we can obtain money and the terms of any financing will be influenced by many different factors, including:

- our revenues,
- the status of competing products in the marketplace,
- our performance in the marketplace,
- our overall financial condition,

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

- our business prospects,
- the perception of our growth potential by the public, including potential lenders,
- our ability to enter into joint venture or licensing relationships to achieve a market presence and
- our progress in developing, marketing and selling our technology or product.

If we cannot obtain adequate financing or if the terms on which we are able to acquire financing are unfavorable, our business and financial condition could be negatively affected. We may have to delay, scale back or eliminate some or all of our development and marketing programs, if any. We may also have to go to third parties to seek financing, and in exchange, we may have to give up rights to some of our technologies, patents, patent applications, potential products or other assets.

WE MAY BE UNABLE TO HIRE AND RETAIN KEY PERSONNEL

Our future success depends on our ability to attract qualified technical personnel capable of working with our technology and product. We may be unable to attract these necessary personnel. If we fail to attract or retain skilled employees, or if a key employee fails to perform in his or her current position, we may be unable to bring our technology or product to the marketplace and to generate sufficient revenues to offset our operating costs.

8

WE MAY BE UNABLE TO OBTAIN AND RETAIN APPROPRIATE PATENT, COPYRIGHT AND TRADEMARK PROTECTION OF OUR PRODUCTS

We protect our intellectual property rights through patents, trademarks, trade names, trade secrets and a variety of other measures. However, these measures may be inadequate to protect our intellectual property or other proprietary information.

- TRADE SECRETS MAY BECOME KNOWN BY THIRD PARTIES. Our trade secrets or proprietary technology may become known or be independently developed by competitors.

- RIGHTS TO PATENTS AND TRADE SECRETS MAY BE INVALIDATED. Disputes may arise with third parties over the ownership of our intellectual property rights. Our patents may be invalidated, circumvented or challenged, and the rights granted under those patents that provide us with a competitive advantage may be nullified.

- PROBLEMS WITH FUTURE PATENT APPLICATIONS. Our pending or future patent applications may not be approved, or the scope of the granted patent may be less than the coverage sought.

- INFRINGEMENT CLAIMS BY THIRD PARTIES. Infringement, invalidity, right to use or ownership claims by third parties or claims for indemnification may be asserted by third parties in the future. If any claims or actions are asserted against us, we can attempt to obtain a license for that third party's intellectual property rights. However, the third party may not provide a license under reasonable terms, or may not provide us with a license at all.

- THIRD PARTIES MAY DEVELOP SIMILAR PRODUCTS. Competitors may develop similar products, duplicate our products or may design around the patents that

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

are owned by us.

- LAWS IN OTHER COUNTRIES MAY INSUFFICIENTLY PROTECT INTELLECTUAL PROPERTY RIGHTS ABROAD. Foreign intellectual property laws may not adequately protect our intellectual property rights abroad. Our failure to protect these rights could adversely affect our business and financial condition.

- LITIGATION MAY BE REQUIRED TO PROTECT INTELLECTUAL PROPERTY RIGHTS. Litigation may be necessary to protect our intellectual property rights and trade secrets, to determine the validity of and scope of the rights of third parties or to defend against claims of infringement or invalidity by third parties. This litigation could be expensive, would divert resources and management's time from our sales and marketing efforts, and could have a materially adverse effect on our business, financial condition and results of operations and on our ability to enter into joint ventures or partnerships with others.

9

WE DO NOT EXPECT TO PAY DIVIDENDS IN THE FORESEEABLE FUTURE

We have never paid cash dividends on our common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable future. The future payment of dividends directly depends upon our future earnings, capital requirements, financial requirements and other factors that our board of directors will consider. Since we do not anticipate paying cash dividends on our common stock, return on your investment, if any, will depend solely on an increase, if any, in the market value of our common stock.

ITEM 2. DESCRIPTION OF PROPERTIES

The Company's corporate headquarters are located at 370 17th Street, Suite 3640, Denver, Colorado 80202. The Company moved into its current office space on June 27, 2001 and has a 5-year lease on the property, expiring in September 2006. The base rent is \$4,850 per month for the remaining term of the lease, plus certain occupancy costs.

NanoPierce Connection was located at 4180 Center Park Drive, Colorado Springs, Colorado 80916. NanoPierce Connection currently has a 3-year lease on the property, expiring in March 2006. The base rent is \$2,600 per month through March 30th, with a \$100 per month increase in base rent each year thereafter for the remaining term of the lease, plus utilities and maintenance expenses. The facility is approximately 4,800 square feet consisting of office space and a small laboratory. The facility also has a clean room. The facility has been abandoned and NanoPierce Connection is in the process of negotiating with the landlord to terminate the lease.

BioAgra is located at 103 Technology Drive, Hinesville, Georgia 31313. BioAgra has leased the facility from the Liberty County Industrial Authority, pursuant to an Industrial Lease Agreement, dated March 1, 2005 for a period of 120 calendar months. At the expiration of the lease term BioAgra has the option to purchase the leased premises (real estate and improvement) for \$500,000. The facility is approximately 30,000 square feet which will consist of both office space and a production area and a research and development laboratory. The facility is located on approximately 7.29 acres.

ITEM 3. LEGAL PROCEEDINGS

HARVEST COURT LITIGATION

In connection with a financing obtained in October 2000, the Company filed

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

various actions in the United States District Court for the District of Colorado against, among others, Harvest Court, LLC, Southridge Capital Investments, LLC, Daniel Pickett, Patricia Singer and Thomson Kernaghan, Ltd. for violations of federal and state securities laws, conspiracy, aiding and abetting and common law fraud among other claims. As a result of various procedural rulings, in January 2002, the United States District Court for the District of Colorado transferred the case to the United States District Court for the Southern District of New York, New York City, New York.

10

In this litigation, Harvest Court, LLC filed counterclaims against the Company, Mr. Metzinger, Ms. Kampmann, Dr. Neuhaus, Dr. Shaw and a number of unrelated third parties. The counterclaims allege violations of federal securities laws and other laws. Harvest Court, LLC is seeking various forms of relief including compensatory and punitive damages. Responsive pleadings have been filed and the litigation is currently in the discovery stage.

In May 2001, Harvest Court, LLC filed suit against the Company in the Supreme Court of the State of New York, County of New York. The suit alleges that the Company breached an October 20, 2000 Stock Purchase Agreement, by not issuing 7,418,895 free trading shares of the Company's common stock in connection with the reset provisions of the Purchase Agreement due on the second reset date and approximately 4,545,303 shares due in connection with the third reset date. Harvest Court, LLC is seeking the delivery of such shares or damages in the alternative. In August 2001, the Supreme Court of the State of New York, County of New York issued a preliminary injunction ordering the Company to reserve and not transfer the shares allegedly due to Harvest Court, LLC. The Company has filed counterclaims seeking various forms of relief against Harvest Court, LLC.

DEPOSITORY TRUST LAWSUIT

In May 2004, the Company filed suit against the Depository Trust and Clearing Corporation ("DTCC"), the Depository Trust Company ("DTC"), and the National Securities Clearing Corporation ("NSCC") in the Second Judicial District Court of the County of Washoe, State of Nevada. The suit alleges multiple claims under the Nevada Revised Statutes 90.570, 90.580, 90.660 and 598A.060 and on other legal bases. The complaint alleges, among other things, that the DTCC, DTC and NSCC acted in concert to operate the "Stock Borrow Program," originally created to address short term delivery failures by sellers of securities in the stock market. According to the complaint, the DTCC, NSCC and DTC conspired to maintain significant open fail deliver positions of millions of shares of the Company's common stock for extended periods of time by using the Stock Borrow Program to cover these open and unsettled positions. The Company was seeking damages in the amount of \$25,000,000 and treble damages. On April 27, 2005, the court granted a motion to dismiss the lawsuit. The Company has filed an appeal to overturn the motion to dismiss the lawsuit.

The Company intends to vigorously prosecute all litigation and does not believe the outcome of the litigation will have a material adverse effect on the financial condition, results of operations or liquidity of the Company. However, it is too early at this time to determine the ultimate outcome of these matters.

Other Litigation

Other than the above mentioned lawsuits, to the knowledge of the management of the Company, there are no material legal proceedings pending or threatened (other than routine litigation incidental to business) to which the Company (or any officer, director, affiliate of beneficial owner of more than 5% of the

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Company's voting securities) is party, or to which property of the Company is subject.

11

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no meetings of security holders and no matters submitted to a vote of security holders during the period covered by this report.

PART II

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

PRICE RANGE OF COMMON STOCK

The Company's common stock is presently quoted on the over-the-counter bulletin board maintained by the National Association of Securities Dealers, Inc. (the "NASD") under the symbol "NPCT." The common stock of the Company is also traded on the Frankfurt Exchange and the Hamburg Stock Exchange under the symbol "NPI."

The following table sets forth the range of high and low quotations for the common stock of each full quarterly period during the fiscal year or equivalent period for the fiscal periods indicated below. The quotations were obtained from information published by the NASD and reflect interdealer prices, without retail mark-up, markdown or commission and may not necessarily represent actual transactions.

2004 FISCAL YEAR -----	HIGH	LOW
September 30, 2003	\$0.27	\$0.21
December 31, 2003	0.29	0.25
March 31, 2004	0.34	0.31
June 30, 2004	0.17	0.15
2005 FISCAL YEAR -----		
September 30, 2004	0.12	0.11
December 31, 2004	0.17	0.16
March 31, 2005	0.11	0.10
June 30, 2005	0.10	0.09

As of June 30, 2005, there were approximately 339 holders of record of the Company's common stock.

DIVIDEND POLICY

The Company has not paid any cash dividends on its common stock in the past and does not anticipate paying any dividends in the foreseeable future. Earnings, if any, are expected to be retained to fund future operations of the Company. There can be no assurance that the Company will pay dividends at any time in the future.

12

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

RECENT SALES OF UNREGISTERED SECURITIES

Unregistered sales for the three years ended June 30, 2003, 2004 and 2005 are set forth below.

DATE	TITLE	NUMBER OF SHARES	HOLDER	CONSIDERATION
8/1/2002	Common Stock	7,000	DJI Partners, LLC	Inv Banking Services
9/4/2002	Common Stock	7,000	DJI Partners, LLC	Inv Banking Services
10/2/2002	Common Stock	50,000	Neptune Investments, Ltd.	\$24,960
10/10/2002	Common Stock	220,000	Neptune Investments, Ltd.	\$100,000
10/17/2002	Common Stock	83,333	David Weilage	\$25,000
10/17/2002	Common Stock	383,333	Martin Ida	\$115,000
10/17/2002	Common Stock	383,333	Robert Ida	\$115,000
10/28/2002	Common Stock	18,796	John Krupa	Exercise Warrant
10/28/2002	Common Stock	18,796	Mallory Smith	Exercise Warrant
10/28/2002	Common Stock	18,796	Robert Lovell	Exercise Warrant
11/18/2002	Common Stock	70,000	Patricia Shonebaum	\$21,000
11/20/2002	Common Stock	50,000	Dennis Ferraro	\$15,000
11/20/2002	Common Stock	166,667	Gerald Doohar	\$50,000
11/20/2002	Common Stock	50,000	Paul Demott	\$15,000
11/20/2002	Common Stock	50,000	Rodney Hock	\$15,000
11/20/2002	Common Stock	50,000	Dennis McGuire	\$15,000
11/20/2002	Common Stock	83,333	Larry S. Pisciotta	\$25,000
11/20/2002	Common Stock	33,333	Vail Valley Emergency Phys Profit	\$10,000
11/21/2002	Common Stock	3,750,000	GrunesSchild, LLC	\$1 Million
11/26/2002	Common Stock	142,858	David Schulze	\$50,000
12/11/2002	Common Stock	125,000	John Provazek	\$50,000
1/10/2003	Common Stock	41,667	John Krupa	\$15,000
1/28/2003	Common Stock	33,333	William Fritz	\$10,000
4/3/2003	Common Stock	1,333,334	Neptune Investments	\$200,000

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

6/20/2003	Common Stock	240,824	John Provazek	\$31,307
7/21/2003	Common Stock	769,231	Neptune Investments	\$100,000
7/22/2003	Common Stock	100,000	Gary Thompson	Outstanding Invoice
7/22/2003	Common Stock	100,000	Charles Lowe	Outstanding Invoice
1/16/2004	Common Stock	16,565	Patricia Schonebaum	Cashless Exercise of Warrant
2/2/2004	Common Stock	17,901	Vail Valley Emergency Physicians	Cashless Exercise of Warrant
2/26/2004	Common Stock	150,598	Hamilton Fund, LLC	Cashless Exercise of Warrant
6/27/2005	Common Stock	1,000,000	Lyons Capital	Consulting Agreement
6/27/2005	Common Stock	1,000,000	Davila Marketing & Capital Group	\$ 150,000 promissory note

13

Exemption From Registration Claimed

The above issuance by the Company of its unregistered securities was made by the Company in reliance upon Section 4(2) of the Securities Act of 1933, as amended (the "Act"). The entities/individuals that purchased the unregistered securities were known to the Company and its management, through pre-existing business relationships. The entities/individuals were provided access to all material information which they requested, and all information necessary to verify such information and was afforded access to management of the Company in connection with the issuance. The holder of the unregistered securities acquired such securities for investment and not with a view toward distribution, acknowledging such intent to the Company. All certificates or agreements representing such securities that were issued contained restrictive legends, prohibiting further transfer of the certificates or agreements representing such securities, without such securities either being first registered or otherwise exempt from registration under the Act in any further resale or disposition.

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS

Certain statements contained in this Form 10-KSB contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties that could cause actual results to differ materially from the results, financial or otherwise, or other expectations described in such forward-looking statements. Any forward-looking statement or statements speak only as of the date on which such statements were made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statements are made or reflect the occurrence of unanticipated events. Therefore, forward-looking statements should not be relied upon as prediction of actual future results.

The independent auditors' report on the Company's consolidated financial statements as of June 30, 2005, and for each of the years in the two-year period then ended, includes a "going concern" explanatory paragraph, that describes substantial doubt about the Company's ability to continue as a going concern.

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Management's plans in regard to the factors prompting the explanatory paragraph are discussed below and also in Note 2 to Notes to the Consolidated Financial Statements.

RESULTS OF OPERATIONS

On April 1, 2003, NanoPierce Card filed insolvency with the Courts of Munich, Germany. On June 8, 2004, NanoPierce Card was dissolved by the Courts of Munich, Germany. NanoPierce Card is presented as discontinued operations in the Company's consolidated financial statements. The Company recognized a gain of \$454,882 on the disposal of NanoPierce Card during the year ended June 30, 2004. During the year ended June 30, 2005, the Company did not have any income or loss from discontinued operations.

During the year ended June 30, 2005, the Company did not recognize any revenues from continuing operations. The Company recognized \$34,258 of revenues from continuing operations during the fiscal year ended June 30, 2004. The revenue generated from continuing operations was from the sale of inlays by ExypnoTech (\$28,449 through December 2003), and \$5,809 from services provided by the Company.

14

The Company recognized \$17,672 in interest income during the fiscal year ended June 30, 2005 compared to \$2,550 during the fiscal year ended June 30, 2004. The increase of \$15,122 is due primarily to the interest earned on funds loaned to a unrelated third party.

Total operating expenses from continuing operations during the fiscal year ended June 30, 2005 were \$872,203, compared to \$1,999,462 for the fiscal year ended June 30, 2004. The decrease of \$1,127,259 is attributable to a decrease in operational activities and spending over the year, as described below.

General and administrative expenses during the fiscal year ended June 30, 2005 were \$872,203 compared to \$1,312,519 for the fiscal year ended June 30, 2004. The decrease of \$440,316 is mainly attributable to decreases in amortization expenses, consulting expenses, legal expenses and accounting expenses. Selling and marketing expenses during the fiscal year ended June 30, 2005 were \$0 compared to \$37,033 during the fiscal year ended June 30, 2004. The decrease of \$37,033 was due to a decrease in marketing activities. Research and development expenses during the fiscal year ended June 30, 2005 were \$0 compared to \$41,849 for the fiscal year ended June 30, 2004. The decrease of \$41,849 was primarily attributable to the reduction in research and development activities over the previous fiscal year.

During the fiscal year ended June 30, 2004, the Company incurred an expense of \$608,061 in connection with the impairment of the intellectual property, patent applications and trademarks owned by the Company. The decision to record an impairment of the intellectual property was based primarily on the overall age of the patents and patent applications underlying the intellectual property combined with the Company's current inactive operational status. After the impairment to the intellectual property, patent applications and trademarks, the book value of the aforementioned items was \$0.

During the fiscal year ended June 30, 2005, the Company recognized a net loss of \$997,616 compared to a net loss of \$1,558,083 during the fiscal year ended June 30, 2005. The decrease of \$560,467 mostly resulted from the decrease of \$1,127,259 in operating expenses offset by the gain of \$454,882 on the disposal of NanoPierce Card during the fiscal year ended June 30, 2004.

LIQUIDITY AND FINANCIAL CONDITION

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Net cash used in operating activities from continuing operations in 2005 was \$544,194, compared to net cash used in operating activities from continuing operations in 2004 of \$1,199,214. In 2005, the net cash used represented a net loss of \$997,616, adjusted for the depreciation expense of \$7,258, equity in losses of affiliates of \$144,323, provision for losses on notes receivable of \$35,000, and amortization of discount on note payable of \$7,272.

In 2004, the net cash used represented a net loss of \$1,558,083, adjusted for the income from discontinued operations of \$454,882, amortization and depreciation expense of \$169,331, impairment charges of \$608,061, equity in losses of affiliates of \$99,922, gain on extinguishment of liabilities of \$52,500, and provision for a doubtful receivable of \$58,074.

15

During the fiscal year ended June 30, 2005, the Company loaned \$314,000 to a unrelated third party and received a payment of \$50,000, which included interest of \$11,442 during the same period. During the fiscal year ended June 30, 2005, the Company loaned Intercell \$35,000. In March 2005, Intercell filed for protection under Chapter 11 of the US Bankruptcy Code. The Company has recorded a provision for this note receivable of \$35,000.

During the fiscal year ended June 30, 2005, in connection with an investment in BioAgra, the Company advanced Xact Resources International \$405,000 to be used for the purchase of a 50% equity interest in BioAgra, LLC for \$1.5 million cash. The purchase was completed in August 2005.

During the fiscal year ended June 30, 2004, the Company advanced \$50,000 to Scimaxx, which was fully reserved for.

During the fiscal year ended June 30, 2004, the Company made investments in machinery and equipment of \$1,575. During the fiscal year ended June 30, 2004, the Company contributed fixed assets with a book value of \$132,000 to the Scimaxx Solutions, LLC as part of the terms of the joint venture.

During the fiscal year ended June 30, 2005, the Company received \$112,800 (net of \$7,200 of offering costs) in connection with the exercise of warrants for 1,200,000 shares of the Company's common stock.

During the fiscal year ended June 30, 2005, the Company received \$41,000 in exchange for an unsecured 5% note payable from Mr. Metzinger, an officer and director of the Company. In August 2005, the note was paid in full.

During the fiscal year ended June 30, 2005, the Company received \$150,000 in exchange for an unsecured 15% per quarter, note payable from an unrelated third party. In connection with the note the Company issued 2,000,000 shares of its restricted common stock (1,000,000 shares were issued in June 2005 and the remaining 1,000,000 shares were issued in July 2005) with a relative fair value of \$81,718, to be amortized over the term of the note. The note was repaid in full in September 2005.

During the fiscal year ended June 30, 2005, the Company received \$25,000 in exchange for an unsecured 8% per annum note payable, from an unrelated third party. In connection with the note the Company issued 1,500,000 shares of its restricted common stock (issued in July 2005) with a relative value of \$21,428, to be amortized over the term of the note. The note was paid in full in August 2005.

During the fiscal year ended June 30, 2004 the Company sold 20,769,231 shares of common stock and granted warrants to purchase 600,000 shares of its

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

common stock at exercise prices ranging from \$0.10 to \$0.25 for net proceeds of \$1,828,000 (net of offering costs of \$272,000). The warrants are exercisable through 2008 and contain a cashless exercise provision. The funds were raised to support operations. In addition, the Company issued 3,850,000 shares of common stock upon the exercise of 3,850,000 warrants for \$347,950 (net of offering costs of \$37,050).

In June 2003, Mr. Metzinger loaned \$10,000 to the Company in exchange for an unsecured 7% note payable due in December 2003, the proceeds of which were utilized for operational purposes. In January 2004, the Company paid Mr. Metzinger the outstanding principal balance of this note, together with all accrued interest.

16

In September 2003, Mr. Metzinger, the President, Chief Executive Officer and director of the Company loaned the Company \$30,000, in exchange for an unsecured 7% note payable due in September 2004. In January, 2004 the Company paid Mr. Metzinger the outstanding principal balance of this note, together with all accrued interest, in full.

In September 2003, Intercell, an affiliate of the Company at the time, loaned the Company \$35,000 in exchange for an unsecured, 7% promissory note due in September 2004. In November 2003, Intercell loaned the Company \$100,000 in exchange for a 7% promissory note due in November 2004. This promissory note was collateralized by an assignment of a 51% interest in the proceeds, if any, the Company may have received in connection with the Financing Agreement litigation. In January 2004, the Company paid the \$135,000 note plus accrued interest of \$2,493.

In 2004, the Company converted accounts payable of \$92,100 into an unsecured non-interest bearing note payable due in March 2005. During the fiscal year ended June 30, 2005, the Company paid the note in full, \$61,737 in 2005 and \$30,363 in 2004.

PLAN OF OPERATIONS

During the year ended June 30, 2005, the Company did not recognize any revenues or income from its equity investment. The Company did not have operations and management of the Company spent a majority of the fiscal year securing funds to purchase a 50% ownership in BioAgra.

In August 2005, the Company was able to raise \$1,535,000 cash through the exercise of 30,700,000 warrants with an exercise price of \$0.05 per share. The Company subsequently completed its purchase of a 50% equity investment in the BioAgra, LLC joint venture for \$1.5 Million in cash.

In August 2005, the Company purchased a 50% equity interest in BioAgra (a Georgia limited liability company) for \$905,000 cash (which includes the \$405,000 advanced to Xact Resources as of June 30, 2005) and a note payable of \$595,000 which was paid in full in September 2005. BioAgra plans to manufacture and sell a beta glucan product, YBG-2000, to be used as a replacement for hormone growth steroids and antibiotics in products such as poultry feed. BioAgra is currently constructing a production line and expects to finish such construction by the end of December 2005. BioAgra anticipates, beginning production and sale of the beta glucan product YBG-2000 in January 2006. The Company anticipates, but cannot be sure, that prior to the end of the fiscal year 2006 it will receive cash disbursements from BioAgra.

Additionally, the Company entered into an agreement with Arizcan Properties, Ltd. ("Arizcan") by which the Company will pay to Arzcan 20% of the cash

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

distributions paid to the Company by and from BioAgra, until such time as Arizcan shall be paid \$800,000.

In September 2005, the Company executed a Subscription Agreement to sell shares of the Company's Preferred Stock with Arizcan Properties. The Subscription Agreement provides for the sale of 200,000 shares of a Class A 8% cumulative and participating preferred shares with a sales price of \$7.50 per share. The Preferred Shares are convertible into 60% of the Company's issued and outstanding post-split shares of the Company's common stock on the date of conversion.

17

In September 2003, the Company formed a joint venture with Scimaxx, LLC. The joint venture, Scimaxx Solutions, LLC was entered into for the purpose of marketing the Company's technology. Scimaxx LLC, is owned by an officer and director of the Company and two former employees of the Company. In return for 50% ownership of the Scimaxx Solutions, LLC, the Company contributed a license to utilize its technology and the facilities and equipment of NanoPierce Connections. In April 2005, Scimaxx ceased operations and during the third quarter of the fiscal year ended June 30, 2005, the Company impaired the value of its investment to \$0. The Company recognized an impairment charge of \$63,544 in equity losses from affiliates.

On December 11, 2003, TagStar Systems, GmbH, a German entity unrelated to the Company, purchased a controlling 51% equity interest in ExypnoTech in exchange for a capital contribution of \$98,000, of which \$62,787 has been received as of June 30, 2005. As a result of this transaction, the Company does not have a controlling interest in ExypnoTech and the Company is only entitled to 49% of the revenues generated by ExypnoTech (and 49% of the dividends, if any, paid by ExypnoTech). As a result of the Company's reduced ownership interest and loss of control of ExypnoTech, the Company deconsolidated ExypnoTech as of December 11, 2003, and began accounting for its investment in ExypnoTech under the equity method of accounting. Under the equity method of accounting, the carrying amount of the Company's investment in ExypnoTech (\$159,642 at June 30, 2005) is adjusted to recognize the Company's proportionate share of ExypnoTech's income (loss) each period.

The Company intends to raise additional funds to support operations of the Company during the 2006 fiscal year. Such funds are to be raised through an offering of convertible preferred stock, the terms of which are in the process of being finalized. Additionally, the Company intends to change its corporate name and most likely to institute a reverse split in connection with recent business events.

To the extent the Company's operations are not sufficient to fund the Company's capital requirements the Company may enter into a revolving loan agreement with financial institutions or attempt to raise capital through the sale of additional capital stock or through the issuance of debt. At the present time the Company does not have a revolving loan agreement with any financial institution nor can the Company provide any assurance that it will be able to enter into any such agreement in the future or be able to raise funds through the further issuance of debt or equity in the Company.

18

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In December 2004, the Financial Accounting Standards Board ("FASB") issued SFAS No. 123(R), Share-Based Payment, which addresses the accounting for

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

share-based payment transactions. SFAS No. 123(R) eliminates the ability to account for share-based compensation transactions using APB 25, and generally requires instead that such transactions be accounted and recognized in the statement of operations based on their fair value. SFAS No. 123(R) will be effective for public companies that file as small business issuers as of the first interim or annual reporting period that begins after December 15, 2005. The Company is currently evaluating the provisions of this standard. Depending upon the number of and terms of options that may be granted in future periods, the implementation of this standard could have a significant impact on the Company's financial position and results of operations in future periods.

In December 2003, the FASB issued Interpretation No. 46R ("FIN 46R"), a revision to SFAS Interpretation No. 46, Consolidation of Variable Interest Entities. FIN 46R clarifies some of the provisions of FIN 46 and exempts certain entities from its requirements. FIN 46R requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or entitled to receive a majority of the entity's residual returns or both. FIN 46R also requires disclosures about variable interest entities that a company is not required to consolidate but in which it has a significant variable interest. FIN 46R became effective for variable interest entities or potential variable interest entities for periods ending after December 15, 2003 for public companies (other than small business issuers), and became effective by the end of the first annual reporting period ending after December 15, 2004 for companies that are small business issuers. FIN 46R did not have an impact on the Company's financial position or results of operations.

CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to deferred revenues; depreciation or fixed assets, valuation of intangible assets such as our intellectual property, financing operations, currency valuations and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

19

The Company believes that the following are some of the more significant accounting policies and methods used by the Company:

- stock based compensation;
- valuation of intellectual property, patent and trademark applications and other long-lived assets;
- equity method investments;
- international operations;
- revenue recognition and deferred revenue;
- litigation; and
- contractual obligations.

Stock-based compensation

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

SFAS No. 123, Accounting for Stock Based Compensation, defines a fair-value-based method of accounting for stock-based employee compensation plans and transactions in which an entity issues its equity instruments to acquire goods or services from non-employees, and encourages but does not require companies to record compensation cost for stock-based employee compensation plans at fair value.

The Company has chosen to account for employee stock-based compensation using the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25 (APB No. 25), Accounting for Stock Issued to Employees, and related interpretations. Accordingly, employee compensation cost for stock options is measured as the excess, if any, of the estimated fair value of the Company's stock at the date of the grant over the amount an employee must pay to acquire the stock.

In December 2004, the Financial Accounting Standards Board ("FASB") issued SFAS No. 123(R), Share-Based Payment, which addresses the accounting for share-based payment transactions. SFAS No. 123(R) eliminates the ability to account for share-based compensation transactions using APB 25, and generally requires instead that such transactions be accounted and recognized in the statement of operations based on their fair value. SFAS No. 123(R) will be effective for public companies that file as small business issuers as of the first interim or annual reporting period that begins after December 15, 2005. The Company is currently evaluating the provisions of this standard. Depending upon the number of and terms of options that may be granted in future periods, the implementation of this standard could have a significant impact on the Company's financial position and results of operations in future periods.

Valuation of intellectual property, patent and trademark applications and other long-lived assets

The Company assesses the impairment of long-lived assets and intangible assets such as intellectual property and patent and trademark applications whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers important which could trigger an impairment review include negative projected operating performance by the Company and significant negative industry or economic trends. At June 30, 2004, management assessed the carrying value of intellectual and other long-lived assets for impairment, and based on this assessment the Company believed that impairment was necessary in the case of the original intellectual property, the patent applications and the trademarks.

20

During 2004, the Company recognized an impairment charge of \$608,061 on the intellectual property, patent applications and trademarks. The Company does not believe that there has been any other impairment to long-lived assets as of June 30, 2005.

Equity method investments

Entities where the Company can exercise significant influence, but not control, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to a company depends on an evaluation of several factors including, among others, representation on the company's board of directors and ownership level, generally 20% to 50% interest in the voting securities of the company including voting rights associated with the Company's holdings in common, preferred and other convertible instruments in the company. Under the equity method of accounting, the Company's share of the earnings or losses of these companies is include in the equity income (loss) section of the consolidated statements of operations.

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

A loss in value of an investment that is other than a temporary decline is recognized as a charge to operations. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. During the year ended June 30, 2005, the Company recorded an impairment charge of approximately \$64,000 related to one of its equity method investments (Note 6).

International operations

The Company's foreign equity investee (ExypnoTech) operations are located in Germany. ExypnoTech transactions are conducted in currencies other than the U.S. dollar, (the currency into which the subsidiaries' historical financial statements have been translated) primarily the Euro. As a result, the Company is exposed to adverse movements in foreign currency exchange rates. In addition, foreign political and economic environment, trade barriers, managing foreign operations and potentially adverse tax consequences. Any of these factors could have a material adverse effect on the Company's financial condition or results of operations in the future.

Revenue recognition and deferred revenue

The Company's revenue recognition policy is significant because future revenue could be a key component of its results or operations. Revenue results are difficult to predict, and any shortfall in revenue or delay in recognizing revenue could cause operating results to vary significantly.

Litigation

The Company is involved in certain legal proceedings, as described in Item 3 of this report and Note 9 to the consolidated financial statements included in this report.

The Company intends to vigorously prosecute these legal proceedings and does not believe the outcome of these proceedings will have a material adverse effect on the financial condition, results of operations or liquidity of the Company. However, it is too early at this time to determine the ultimate outcome of these matters.

Contractual obligations

For more information on the Company's contractual obligations on operating leases, refer to Note 9 of the consolidated financial statements included in this report. At June 30, 2005, the Company's commitments under these obligations were as follows:

	OPERATING LEASES

Year ending June 30,	
2006	83,401
2007	14,550
-----	-----
	\$ 97,951
	=====

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

21

ITEM 7. FINANCIAL STATEMENTS

The consolidated financial statements and related financial information required to be filed are indexed on page F-1 and are incorporated herein.

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 8A. CONTROLS AND PROCEDURES

As of the end of the period covered by this Annual Report on Form 10-KSB, the Company carried out an evaluation, under the supervision and with the participation of the Company's President and Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based upon such evaluation, such officers have concluded that the Company's disclosure controls and procedures are effective in alerting them, on a timely basis, to material information relating to the Company required to be included in this Annual Report on Form 10-KSB.

There have been no significant changes to the Company's internal controls over financial reporting that have materially affected, or are reasonably likely to materially effect, the Company's internal controls over financial reporting.

ITEM 8B. OTHER INFORMATION

None.

PART III

ITEM 9. DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY

FINANCIAL EXPERT

The Company's Board of Directors does not have a designated Financial Expert, as defined by the SEC, due to factors including the Company's operational status, and the limited number of transactions, accounts and balances that the Company maintains. In addition, the estimates of cost that the Company would be required to incur in identifying and designating a Financial Expert are deemed not to be in the best interest of the Company.

22

EXECUTIVE OFFICERS AND DIRECTORS

The executive officers, directors and significant employees of the Company are as follows:

NAME AND AGE	POSITION	PERIOD
Paul H. Metzinger (66)	Director, President, and Chief Executive Officer, General Manager of	December 1998 to present January 2000 to June 2003

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

	NanoPierce Card	
Dr. Herbert J. Neuhaus (44)	Director, Former Executive Vice President of Technology & Marketing, President & Chief Executive Officer of NanoPierce Connection	January 1999 to present January 2002 to September 2003
Kristi J. Kampmann (32)	Chief Financial Officer, Secretary	October 1999 to present February 1998 to present
Dr. Robert Shaw (65)	Director	October 2000 to present
John Hoback (65)	Director	April 2002 to present

The directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified. The Board of Directors elects the officers at its annual meeting immediately following the shareholders annual meeting and hold office until they resign or are removed from office. There are no family relationships that exist between any director, executive officer, significant employee or person nominated or chosen by the Company to become a director or executive officer. The Company has established audit, incentive compensation and nominating committees, consisting of the independent directors.

BIOGRAPHICAL INFORMATION ON OFFICERS, DIRECTORS AND SIGNIFICANT EMPLOYEES

PAUL H. METZINGER. Mr. Metzinger was President and Chief Executive Officer of the Company from February 26, 1998 to May 6, 1998 and has served in that same capacity from December 1, 1998 to present. He has been a director of the Company since February 26, 1998. He served as the General Manager of NanoPierce Card from January 2000 to June 2003. In addition, he served as the President, Chief Executive Officer and a Director of Intercell International Corporation from June 1996 to October 2003 and from September 30, 2004 to March 16, 2005. Prior to becoming a director and officer of the Company and Intercell International Corporation, Mr. Metzinger served as Intercell's General Counsel and practiced securities law in Denver, Colorado for over 32 years. Mr. Metzinger received his J.D. degree in 1967 from Creighton University Law School and his L.L.M. from Georgetown University in 1969.

23

HERBERT J. NEUHAUS, PH.D. Dr. Neuhaus has been the Executive Vice President of Marketing and Technology and a Director of the Company since January 1, 1999. He has been the President and Chief Executive Officer of NanoPierce Connection since January 2002. Dr. Neuhaus previously served as the Managing Director of Particle Interconnect Corporation from August 18, 1997 to November 1, 1997. From August 1989 to August 1997, he was associated with the Electronic Material Venture Group in the New Business Development Department of Amoco Chemical Company, Naperville, Illinois. While associated with Amoco Chemical Company he held among other positions: Business Development Manger/Team Leader; Project Manager --High Density Interconnect; Product Manager MCM Products and as a research scientist.

Dr. Neuhaus received his Ph.D. degree in Physics from the Massachusetts Institute of Technology, Cambridge, Massachusetts in 1989 and his BS in Physics from Clemson University, Clemson, South Carolina in 1980.

KRISTI J. KAMPMANN. Ms. Kampmann was appointed the Chief Financial Officer of the Company on October 15, 1999. Ms. Kampmann has been Secretary of the

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Company since February 1998. Ms. Kampmann has served as a manager of ExypnoTech, LLC since June 2004. She has served as the Chief Financial Officer of Intercell International Corporation since October 1, 2003 and as Secretary of Intercell International Corporation since July 28, 1999. Since June 1997, she has been the administrative assistant to the Chief Executive Officer and Chief Financial Officer; in addition, during the same period she served in the same capacity to the Chief Executive Officer of Intercell. From April 1996 to June 1997, she served as a paralegal and administrative assistant for Paul H. Metzinger, P.C. Ms. Kampmann received an MBA from the University of Colorado, Denver in December 2001. Ms. Kampmann graduated from the Denver Paralegal Institute in 1996 and received a B.A. from the University of Minnesota in Morris in 1995, majoring in Political Science with a minor in Business Management.

DR. ROBERT SHAW. Dr. Shaw has been a director of the Company since October 31, 2000. Dr. Shaw currently is an Assistant Professor of Physics at Farleigh Dickinson University where he has served on the faculty since September 1988. Dr. Shaw also performs professional research in his academic areas of specialty, and has held, among others, the positions of Research Chemist at the American Cyanamid Research Laboratories, Stamford; Senior Research Physicist at Exxon Research and Engineering Company; Manager of New Business Development at Exxon Enterprises, Exxon Corporation, New York, NY; and President of Robert Shaw Associates, Inc., Chatham, NJ.

Dr. Shaw received his Ph.D. in Solid State Physics from Cambridge University, Cambridge, England. He was among the first to conduct academic research on electronic conduction mechanisms in amorphous semiconductors. He received a B.S. in Inorganic Chemistry with a minor in Nuclear Physics from North Carolina State University, Raleigh, NC.

24

JOHN HOBACK. Mr. Hoback has been a director of the Company since April 2002. Mr. Hoback currently serves as the President of Z&H Enterprises Solutions, Ltd., which position he has held since 2000. Among other positions, Mr. Hoback was the Director of Marketing and Sales of CTS from 1999 to 2000 and was the Venture Manager of Electronics with Amoco Chemical from 1988 to 1999.

CODE OF ETHICS

The Company in January 2004 adopted a Code of Ethics that applies to the Chief Executive Officer, Chief Financial Officer, Controller, Principal Accounting Officer and those employees performing similar functions.

25

ITEM 10. EXECUTIVE COMPENSATION

The following table sets forth certain information concerning compensation paid by the Company to the Chief Executive Officer and the Company's three most highly compensated executive officers for the fiscal years ended June 30, 2005, 2004 and 2003 (the "Named Executive Officers"):

SUMMARY COMPENSATION TABLE

ANNUAL COMPENSATION

LONG TERM

AWARDS

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

NAME & PRINCIPAL POSITION	YEAR	SALARY (\$)	BONUS (\$)	OTHER ANNUAL COMPENSA-TION	RESTRICTED STOCK AWARDS (\$)	SECURITIES UNDERLYING OPTIONS/ SARS (#)
Paul H. Metzinger, Director, President & CEO(1)	2005	\$ 136,785	\$ -0-	\$ -0-	\$ -0-	-0-
	2004	\$ 114,583	\$ -0-	\$ -0-	\$ -0-	-0-
	2003	\$ 132,500	\$ -0-	\$ -0-	\$ -0-	-0-
Dr. Herbert J. Neuhaus, Director, Ex. VP of Technology & Marketing, Pre & CEO of NanoPierce Connection (2)	2005	\$ -0-	\$ -0-	\$ -0-	\$ -0-	-0-
	2004	\$ 16,668	\$ -0-	\$ -0-	\$ -0-	-0-
	2003	\$ 148,333	\$ -0-	\$ -0-	\$ -0-	-0-
Dr. Michael E. Wernle, Director, Ex. VP of Strategic Business Dvlpmt, Pres & CEO of ExypnoTech (3)	2005	\$ -0-	\$ -0-	\$ -0-	\$ -0-	-0-
	2004	\$ -0-	\$ -0-	\$ -0-	\$ -0-	-0-
	2003	\$ 128,000	\$ -0-	\$ -0-	\$ -0-	365,000
Kristi J. Kampmann, Chief Financial Officer & Secretary(4)	2005	\$ 80,625	\$ -0-	\$ -0-	\$ -0-	-0-
	2004	\$ 37,492	\$ -0-	\$ -0-	\$ -0-	-0-
	2003	\$ 58,125	\$ -0-	\$ -0-	\$ -0-	-0-

1 Paul Metzinger has served as President & CEO since December 1998. He is compensated pursuant to a written Employment Agreement, dated March 15, 2004 at an annual salary of \$150,000. Over the three year period Mr. Metzinger has taken salary cuts when necessary.

2 Dr. Neuhaus has served as the Executive Vice President of Technology and Marketing since January 1999. He served as the President and CEO of NanoPierce Connection from January 2002 to September 2003. He was compensated pursuant to a written Employment Agreement, dated January 2002 at an annual salary of \$200,000. This employment agreement was terminated in September 2003 and Dr. Neuhaus is no longer a paid employee of the Company and/or its subsidiaries.

3 Dr. Wernle served as the Executive Vice President of Strategic Business Development until September 2003. He served as the President & CEO of NanoPierce Card from January 2000 until May 2003. He served as the President & CEO of ExypnoTech, from February 2002 to August 2003. He was compensated pursuant to a written Employment Agreement with NanoPierce Card, dated February 1, 2000, at an annual salary of \$160,000 (181,000 Euros). As of August 2003, Dr. Wernle no longer is a paid employee of the Company and/or its subsidiaries.

4 Kristi Kampmann has served as the Chief Financial Officer since October 1999. She is compensated pursuant to a written Employment Agreement, dated March 15, 2004. During the year ended June 30, 2005, Ms. Kampmann received a gross monthly salary of \$7,500 for 7 months, in March 2005 it was reduced to \$6,250 per month.

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

The foregoing compensation table does not include certain fringe benefits made available on a nondiscriminatory basis to all Company employees such as group health insurance, dental insurance, long-term disability insurance, vacation and sick leave. In addition, the Company makes available certain non-monetary benefits to its executive officers with a view to acquiring and retaining qualified personnel and facilitating job performance. The Company considers such benefits to be ordinary and incidental business costs and expenses. The aggregate value of such benefits in the case of each executive officer listed in the above table, which cannot be precisely ascertained but which is less than 10% of the cash compensation paid to each such executive officer, is not included in such table.

OPTION/SAR GRANTS TABLE

There were no grants of stock options to the Company's executive officers during the fiscal year ended June 30, 2005.

AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR END OPTION/SAR VALUES

The following table provides information relating to the exercise of stock options during the fiscal year ended June 30, 2005 by the Company's executive officers and the 2005 fiscal year-end value of unexercised options.

NAME	SHARES ACQUIRED ON EXERCISE (#)	VALUE REALIZED (\$)	NUMBER OF SECURITIES UNDERLYING UNEXERCISED OPTIONS/SARS AT FY-END	VALUE OF UNEXERCISED IN-THE-MONEY OPTIONS/SAR AT FY-END (\$)
			EXERCISABLE/UNEXERCISABLE -----	EXERCISABLE/UNEXERCISABLE -----
Paul H. Metzinger	0	0	2,500,000/0	\$ 237,500/0
Dr. Herbert J. Neuhaus	0	0	1,350,000/0	\$ 128,250/0
Kristi J.Kampmann	0	0	325,000/0	\$ 30,875/0

1 The average of the closing bid and asked price of the Common Stock on June 30, 2005 (\$0.095) was used to calculate the option value.

EMPLOYMENT AGREEMENTS

On March 15, 2004, the Company entered into an employment agreement with Paul H. Metzinger to serve as President and Chief Executive Officer of the Company. The employment agreement with Mr. Metzinger expires March 14, 2008. Pursuant to his employment agreement, the Company agreed to pay Mr. Metzinger an annual salary of \$150,000. In March 2005, Mr. Metzinger took a salary cut to receive an annual salary of \$105,000.

On March 15, 2004, the Company entered into an employment agreement with Kristi J. Kampmann to serve as the Chief Financial Officer of the Company. The employment agreement with Ms. Kampmann expires on March 14, 2008. Pursuant to

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

her employment agreement, the Company agreed to pay Ms. Kampmann an annual salary of \$30,000. During the year ended June 30, 2005, Ms. Kampmann received a salary increase for an annual salary of \$90,000, but in March 2005 took a salary cut to receive an annual salary of \$75,000.

In connection with the Employment Agreements, generally, the Company or the employee may terminate the Employment Agreement at any time with or without cause. In the event the Company terminates an Employment Agreement for cause or the employee terminates his or her Employee Agreement without cause, all of such employee's rights to compensation would cease upon the date of such termination. If the Company terminates an Employment Agreement without cause, the such employee terminates his or her Employment Agreement for cause, or in the event of a change in control, the Company is required to pay to such employee all compensation and other benefits that would have accrued and/or been payable to that employee during the full term of the Employment Agreement.

A change of control is considered to have occurred when, as a result of any type of corporate reorganization, execution of proxies, voting trusts or similar arrangements, a person or group of persons (other than incumbent officers, directors and principal shareholders of the Company) acquires sufficient control to elect more than a majority of the Company's Board of Directors, acquires 50% or more of the voting shares of the Company, or the Company adopts a plan of dissolution or liquidation. The Employment Agreement also include a non-compete and nondisclosure provisions in which each employee agrees not to compete with or disclose confidential information regarding the Company and its business during the term of the Employment Agreement and for a period of one year thereafter.

COMPENSATION PURSUANT TO PLANS

STOCK OPTION PLANS. The Company has two Stock Option Plans. As of June 30, 2005, 7,047,524 options are outstanding under the 1998 Compensatory Stock Option Plan and 1,740,000 options are outstanding under the 2000 Compensatory Stock Option Plan, for a total of 8,787,524 options outstanding. A total of 8,637,524 options are exercisable at June 30, 2005, under these plans. During the fiscal year ended June 30, 2005, the Company did not grant any options. The Company has reserved 7,500,000 shares of common stock for issuance under the 1998 Compensatory Stock Option Plan. In January 2002, the Company's Board of Directors passed a resolution closing the 1998 Compensatory Stock Option Plan for issuance of new options. The Company has reserved 5,000,000 shares of common stock for issuance under the 2000 Compensatory Stock Option Plan.

During the fiscal year ended June 30, 2005, there was no action taken to reprice any options held by any officers, directors or employees.

28

COMPENSATION OF DIRECTORS

The Company holds quarterly meetings of the board of directors. Although the Company does not have any standard arrangements pursuant to which our directors are compensated for any services provided as a director or for attendance at meetings of the board of directors, if the financial situation of the Company is adequate, the Company compensates directors \$1,000 per meeting, plus reasonable travel expenses.

During the fiscal year ended June 30, 2005, the officers and directors were not compensated for attendance at board meetings.

29

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCK HOLDER MATTERS

BENEFICIAL OWNERSHIP

The following table sets forth certain information regarding the beneficial ownership of outstanding shares of the Company's common stock as of June 30, 2005 on a fully diluted basis, by (a) each person known by the Company to own beneficially 5% or more of the outstanding shares of common stock, (b) the Company's directors, Chief Executive Officer and executive officers whose total compensation exceeded \$100,000 for the last fiscal year, and (c) all directors and executive officers of the Company as a group.

NAME, ADDRESS & NATURE OF BENEFICIAL OWNER	TITLE OF CLASS	AMOUNT	PERCENT OF CLASS (7)
The Paul H. Metzinger Trust Paul H. Metzinger, President & CEO, Director 370 17th Street, Suite 3640 Denver, CO 80202	Common Stock	4,543,188 (1)	2.68%
The Cheri L. Metzinger Trust Cheri L. Metzinger, Wife of Paul H. Metzinger 3236 Jellison Street Wheatridge, CO 80033	Common Stock	4,543,188 (2)	2.68%
Dr. Herbert J. Neuhaus, Director, 770 Maroonglen Court Colorado Springs, CO 80906	Common Stock	1,350,000 (3)	0.80%
Kristi J. Kampmann, Chief Financial Officer & Secretary 370 17th Street, Suite 3640 Denver, CO 80202	Common Stock	344,080 (4)	0.20%
Dr. Robert E. Shaw, Director 8 Nicklaus Court Florham Park, NJ 07932	Options to purchase Common Stock	400,000 (5)	0.24%
John Hoback, Director 20 White Heron Lake East Stroudsburg, PA 18301	Options to purchase Common Stock	400,000 (6)	0.24%
All Officers & Directors as a Group (7 persons)	Common Stock	7,037,268	4.15%

1 Includes 1,072,937 common shares held directly and beneficially; 970,251

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

common shares that Mr. Metzinger owns beneficially through his wife and options held by Mr. Metzinger consisting of options to purchase 500,000 shares exercisable at \$2.125 per share, options to purchase 500,000 shares exercisable at \$0.52 per share and options to purchase 1,500,000 shares exercisable at \$0.3250 per share.

2 Cheri L. Metzinger is the wife of Mr. Paul H. Metzinger, the Chief Executive Officer and President of the Company. This includes 970,251 shares held directly and beneficially and 1,072,937 common shares and 2,000,000 common shares subject to options owned beneficially by her husband.

30

3 Based on options to purchase 500,000 shares exercisable at \$2.125 per share, options to purchase 100,000 shares exercisable at \$2.75 per share, options to purchase 250,000 shares exercisable at \$0.52 per share and options to purchase 500,000 shares exercisable at \$0.20 per share.

4 Based on 19,080 common shares and options to purchase 100,000 shares exercisable at \$0.84 per share, options to purchase 75,000 shares exercisable at \$2.125 per share, options to purchase 50,000 shares exercisable at \$2.75 per share, options to purchase 50,000 shares exercisable at \$0.52 per share and options to purchase 50,000 shares exercisable at \$0.3250 per share.

5 Based on options to purchase 250,000 shares exercisable at \$0.97 per share, options to purchase 50,000 shares exercisable at \$0.67 per share, and options to purchase 100,000 shares exercisable at \$2.00 per share.

6 Based on options to purchase 300,000 shares exercisable at \$0.70 per share and options to purchase 100,000 shares exercisable at \$0.70 per share.

7 Based on 93,259,033 shares of common stock issued and outstanding on June 30, 2005, assuming exercise of all 8,787,524 presently exercisable options and exercise of 67,394,353 outstanding warrants, there would be 169,440,910 shares outstanding. Mr. Metzinger's and Mrs. Metzinger's stock ownership are not duplicated in this computation.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

The following table provides information as of June 30, 2005 regarding compensation plans (including individual compensation arrangements) under which shares of our common stock are authorized for issuance. No class of our securities other than our common stock or options to purchase our common stock is authorized for issuance under any of our equity compensation plans.

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
	(a)	(b)	(c)
Equity compensation plans approved by security holders	0	-	0
Equity compensation plans			

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

not approved by security holders(1)	8,787,524	\$	1.00	3,712,476

Total	8,787,524	\$	1.00	3,712,476

(1) The material features of the plans not approved by the security holders are described herein under "ITEM 10-EXECUTIVE COMPENSATION-Compensation Pursuant to Plans."

31

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

In June 2005, Mr. Metzinger loaned the Company \$41,000, in exchange for an unsecured 5% note payable due December 31, 2005. In August 2005, the Company paid the outstanding principal balance of this note and all accrued interest thereon in full.

In March 2004, the Company entered into employment agreements, as previously discussed, with Mr. Metzinger, the President and Chief Executive Officer and a Director of the Company, and with Ms. Kampmann, the Chief Financial Officer and Secretary of the Company.

In September 2003, the Company entered into a joint venture agreement with Scimaxx, LLC to support the marketing of the Company's technology. The owners of Scimaxx, LLC include Dr. Neuhaus, a director and a former officer of the Company and several former employees of the Company.

In June 2003, Mr. Metzinger loaned the Company \$10,000, in exchange for an unsecured 7% note payable due in December 2003. In January 2004, the Company paid Mr. Metzinger the outstanding principal balance of this note and all accrued interest thereon in full.

In September 2003, Mr. Metzinger, the President, Chief Executive Officer and director of the Company loaned the Company \$30,000, in exchange for an unsecured 7% note payable due in September 2004. In January, 2004 the Company paid Mr. Metzinger the outstanding principal balance of this note, together with all accrued interest, in full.

PART IV

ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K

The following documents are filed as a part of this Report.

(i) Financial Statements. See Index to Financial Statements and Schedule on page F-2 of this Report.

(ii) Exhibits. The following is a complete list of exhibits filed as part of this Form 10-KSB. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-B.

32

EXHIBIT NO.	DESCRIPTION
-------------	-------------

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

- 2 Agreement dated February 26, 1998, by and among the Company, Particle Interconnect Corporation and Intercell Corporation (4)
- 2.02 Application and Development Agreement, dated April 15, 1999, by and among the Company and Multitape & Co., GmbH, KG. (2)
- 2.03 Technology Cooperation Agreement, dated May 17, 1999, by and among the Company and Meinen, Zeigel & Co. (2)
- 2.04 Technology Development Agreement, dated June 11, 1999, by and among the Company and ORGA Kartensysteme, GmbH. (2)
- 2.05 Agreement-In-Principle, dated May 18, 1999, by and among the Company and Cirrex Corporation. (2)
- 4.01 The Articles of Incorporation of the Company (3)
- 4.02 Amendment to the Articles of Incorporation of the Company filed with the Nevada Secretary of State on March 20, 2002 (3)
- 4.03 Amendment to Articles of Incorporation filed with the Nevada Secretary of State on March 20, 2002
- 4.04 Certificate of Designation of Rights and Preferences of the Series A Preferred Stock (4)
- 4.05 Certificate of Designation of Rights and Preferences of the Series B Preferred Stock (5)
- 4.06 Certificate of Designation of Rights and Preferences of the Series C Preferred Stock (5)
- 4.07 Form of Common Stock Certificate (3)
- 4.08 The Amended and Restated By-laws of the Company (6)
- 10.01 Employment Agreement, dated March 15, 2004, between Paul H. Metzinger and the Company (7)
- 10.02 Employment Agreement, dated March 15, 2004, between Kristi J. Kampmann and the Company (7)
- 10.03 Operating Agreement, dated August 15, 2005, between the Company and Xact Resources International, Inc. for BioAgra, LLC.(8)
- 11 Statement regarding Computation of Per Share Loss (1)
- 21 Subsidiaries of the Company (1)
- 23 Consent of Independent Registered Public Accounting Firm (1)
- 31 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act (1)
- 32 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act (1)

-
- 1 Filed herewith.
 - 2 Incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30, 1999.
 - 3 Incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30, 1998.
 - 4 Incorporated by reference to the Company's Current Report on Form 8-K, dated February 26, 1998.
 - 5 Incorporated by reference to the Company's Current Report on Form 8-K, dated July 23, 1998.
 - 6 Incorporated by reference to Amendment No. 1 to the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2003.
 - 7 Incorporated by reference to the Company's Quarterly Report on Form 10-QSB for the fiscal quarter ended March 31, 2004.
 - 8 Incorporated by reference to the Company's Current Report on Form 8-K, dated August 12, 2005.

33

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The aggregate fees billed by GHP Horwath, P.C. (previously known as Gelfond Hochstadt Pangburn, P.C.), the Company's independent registered public

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

accounting firm, for professional services in the fiscal years ended June 30, 2005 and 2004 are as follows:

Services Rendered	2005	2004
Audit Fees	\$50,660	\$57,060
Audit Related Fees	0	0
All Other Fees	0	0

The Company's corporate tax returns are prepared by the firm of Thompson & Lowe, P.C. Fees for the fiscal years ended June 30, 2005 and 2004 were \$15,280 and \$10,000, respectively.

The engagement of the Company's independent registered public accounting firm was approved by the Company's Board of Directors prior to the start of the audit for the fiscal year ended June 30, 2005.

34

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NANOPIERCE TECHNOLOGIES, INC.
(a Nevada corporation)

Date: October 3, 2005

By: /s/ Paul H. Metzinger

Paul H. Metzinger, Director, Chief
Executive Officer & President

Date: October 3, 2005

By: /s/ Kristi J. Kampmann

Kristi J. Kampmann, Chief Financial
Officer & Chief Accounting Officer

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date: October 3, 2005

By: /s/ Paul H. Metzinger

Paul H. Metzinger, Director, Chief

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Executive Officer & President

Date: October 3, 2005

By: /s/ Herbert J. Neuhaus

Herbert J. Neuhaus, Director &
Executive Vice-President of
Technology & Marketing

Date: October 3, 2005

By: /s/ Robert Shaw

Robert Shaw, Director

Date: October 3, 2005

By: /s/ John Hoback

John Hoback, Director

35

SUPPLEMENTAL INFORMATION TO BE FURNISHED WITH REPORTS FILED PURSUANT TO SECTION 15(d) OF THE EXCHANGE ACT BY NON-REPORTING ISSUERS

No annual report covering the Company's fiscal year ended June 30, 2005, nor any proxy material, has been sent to security holders of the Company.

NANOPIERCE TECHNOLOGIES , INC. AND SUBSIDIARIES INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm	F-1
Consolidated Financial Statements:	
Consolidated Balance Sheet - June 30, 2005	F-2
Consolidated Statements of Operations- Years ended June 30, 2005 and 2004	F-3
Consolidated Statements of Comprehensive Loss - Years ended June 30, 2005 and 2004	F-4
Consolidated Statements of Changes in Shareholders' Equity - Years ended June 30, 2005 and 2004	F-5
Consolidated Statements of Cash Flows - Years ended June 30, 2005 and 2004	F-7
Notes to Consolidated Financial Statements	F-9

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Board of Directors
Nanopierce Technologies, Inc.
Denver, Colorado

We have audited the accompanying consolidated balance sheet of Nanopierce Technologies, Inc. and subsidiaries as of June 30, 2005, and the related consolidated statements of operations, comprehensive loss, changes in shareholders' equity and cash flows for each of the years in the two-year period ended June 30, 2005. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Nanopierce Technologies, Inc. and subsidiaries as of June 30, 2005, and the results of their operations and their cash flows for each of the years in the two-year period ended June 30, 2005, in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company reported a net loss of \$997,616 for the year ended June 30, 2005, and an accumulated deficit of \$23,629,319 as of June 30, 2005. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ GHP HORWATH, P.C.

Denver, Colorado
September 26, 2005

F-1

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Balance Sheet
June 30, 2005

Assets

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Current assets:	
Cash and cash equivalents	\$ 25,835
Interest receivable	3,823
Notes receivable, net (Note 5)	275,442
Prepaid expenses	91,306

Total current assets	396,406

Property and equipment:	
Office equipment and furniture	66,356
Less accumulated depreciation	(50,514)

	15,842

Other assets:	
Advances receivable (Note 5)	405,000
Deposits and other	19,285
Investments in affiliates (Note 6)	159,642

	583,927

Total assets	\$ 996,175
	=====
Liabilities and Shareholders' Equity	

Current liabilities:	
Accounts payable	\$ 214,891
Accrued liabilities	18,227
Other liability (Note 8)	90,000
Notes payable, net of discount of \$95,874 (Note 7)	119,690

Total liabilities (all current)	442,808

Commitments and contingencies (Notes 4,7 and 9)	
Shareholders' equity (Notes 7 and 8):	
Preferred stock; \$0.0001 par value; 5,000,000 shares authorized; none issued and outstanding	
Common stock; \$0.0001 par value; 200,000,000 shares authorized; 93,259,033 shares issued and outstanding	9,326
Additional paid-in capital	24,050,517
Accumulated other comprehensive income	122,843
Accumulated deficit	(23,629,319)

Total shareholders' equity	553,367

Total liabilities and shareholders' equity	\$ 996,175
	=====

See notes to consolidated financial statements.

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

F-2

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
 Consolidated Statements of Operations
 Years Ended June 30, 2005 and 2004

	2005	2004
	-----	-----
Revenues	\$ -	34,258
	-----	-----
Operating expenses:		
General and administrative	872,203	1,312,519
Research and development	-	41,849
Selling and marketing	-	37,033
Impairment of intellectual property (Note 1)	-	608,061
	-----	-----
	872,203	1,999,462
	-----	-----
Loss from operations	(872,203)	(1,965,204)
	-----	-----
Other income (expense):		
Other income	10,618	-
Interest income	17,672	2,550
Extinguishment of liabilities (Note 7)	-	52,500
Equity losses of affiliates (Note 6)	(144,323)	(99,922)
Interest expense	(9,301)	(1,683)
Interest expense, related party	(79)	(1,206)
	-----	-----
	(125,413)	(47,761)
	-----	-----
Loss from continuing operations	(997,616)	(2,012,965)
	-----	-----
Discontinued operations; income from operations of subsidiary (Note 3)	-	454,882
	-----	-----
Net loss	\$ (997,616)	(1,558,083)
	=====	=====
Basic and diluted loss per share:		
Loss from continuing operations	\$ (0.01)	(0.03)
Income from discontinued operations	-	0.01
	-----	-----
Net loss per share, basic and diluted	\$ (0.01)	(0.02)
	=====	=====
Weighted average number of common shares outstanding	90,899,581	75,116,717
	=====	=====

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

See notes to consolidated financial statements.

F-3

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Statements of Comprehensive Loss
Years Ended June 30, 2005 and 2004

	2005	2004
	-----	-----
Net loss	\$ (997,616)	(1,558,083)
Change in unrealized loss on securities	(379)	(141)
Change in foreign currency translation adjustments	-	(66,727)
	-----	-----
Comprehensive loss	\$ (997,995)	(1,624,951)
	=====	=====

See notes to consolidated financial statements.

F-4

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Statement of Changes in Shareholders' Equity
Years Ended June 30, 2005 and 2004

	Common stock		Additional	Accumulated	Accumu
	Shares	Amount	paid-in	other	defi
	-----	-----	-----	-----	-----
Balances, July 1, 2003	65,054,738	\$ 6,505	21,567,807	190,090	(21,0
Common stock and warrants issued for cash (net of offering costs of \$272,000)	20,769,231	2,077	1,825,923	-	
Common stock issued in satisfaction of payable	200,000	20	3,615	-	
Common stock issued upon exercise of warrants (net of offering costs of \$37,050)	3,850,000	385	347,565	-	

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Common stock issued upon cashless exercise of warrants	185,064	19	(19)	-	
Net loss	-	-	-	-	(1,5
Other comprehensive loss:					
Change in unrealized gain on securities	-	-	-	(141)	
Foreign currency translation adjustments	-	-	-	(66,727)	
Balances, June 30, 2004	90,059,033	\$ 9,006	23,744,891	123,222	(22,6

See notes to consolidated financial statements.

F-5

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Statement of Changes in Shareholders' Equity
Years Ended June 30, 2005 and 2004

	Common stock		Additional paid-in capital	Accumulated other comprehensive Income	Accumu defi
	Shares	Amount			
Balances, July 1, 2004	90,059,033	\$ 9,006	23,744,891	123,222	(22,63
Common stock issued upon exercise of warrants (net of offering costs of \$7,200)	1,200,000	120	112,680	-	
Common stock issued for deferred consulting costs	1,000,000	100	89,900	-	
Common stock issued upon issuance of note payable	1,000,000	100	102,796	-	
Common stock to be issued	-	-	250	-	
Net loss	-	-	-	-	(99
Other comprehensive loss:					
Change in unrealized gain on securities	-	-	-	(379)	

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Balances,	-----	-----	-----	-----	-----
June 30, 2005	93,259,033	\$ 9,326	24,050,517	122,843	(23,62
	=====	=====	=====	=====	=====

See notes to consolidated financial statements.

F-6

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
Years Ended June 30, 2005 and 2004

	2005	2004
	-----	-----
Cash flows from operating activities:		
Net loss	\$ (997,616)	(1,558,083)
	-----	-----
Adjustments to reconcile net loss to net cash used in operating activities from continuing operations:		
Income from discontinued operations	-	(454,882)
Amortization expense	7,500	158,674
Depreciation expense	7,258	10,657
Equity losses of affiliates	144,323	99,922
Gain on extinguishment of liabilities	-	(52,500)
Provision for losses on receivables	35,000	58,074
Amortization of discount on note payable	7,272	-
Amortization of deferred consulting costs	-	122,459
Impairment of intellectual property and equipment	-	608,061
Changes in operating assets and liabilities:		
Decrease (increase) in accounts receivable	1,986	(11,883)
Decrease in prepaid expenses	35,921	8,646
Increase (decrease) in accounts payable	105,935	(188,359)
Increase in accrued liabilities	18,227	-
Increase in other liability	90,000	-
	-----	-----
Total adjustments	453,422	358,869
	-----	-----
Net cash used in operating activities from continuing operations	(544,194)	(1,199,214)
	-----	-----
Cash flows from investing activities:		
Advances to equity investee	-	(50,000)
Increase in notes receivable	(349,000)	-
Repayment of note receivable	38,558	-
Increase in advances receivable	(405,000)	-
Increase in patent and trademark applications	-	(68,189)
Purchases of property and equipment	-	(1,575)
Cash effect of ExypnoTech deconsolidation	-	(115,151)
	-----	-----
Net cash used in investing activities from continuing operations	(715,442)	(234,915)
	-----	-----

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Cash flows from financing activities:		
Exercise of warrants and common stock issued for cash	112,800	2,175,950
Payment of notes payable	(61,737)	(205,700)
Proceeds from issuance of notes payable and common stock	216,000	165,000
	-----	-----
Net cash provided by financing activities from continuing operations	267,063	2,135,250
	-----	-----
Effect of exchange rate changes on cash and cash equivalents	-	127,038
	-----	-----
Net cash used in discontinued operations	-	(10,492)
	-----	-----
Net (decrease) increase in cash and cash equivalents	(992,573)	817,667
Cash and cash equivalents, beginning	1,018,408	200,741
	-----	-----
Cash and cash equivalents, ending	\$ 25,835	1,018,408
	=====	=====

(Continued) F-7

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
Years Ended June 30, 2005 and 2004
Continued

	2005	2004
	-----	-----
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 17	2,851
	=====	=====
Supplemental disclosure of non-cash investing and financing activities:		
Issuance of common stock and common stock to be issued in connection with notes payable	\$ 103,146	-
	=====	=====
Issuance of common stock in exchange for deferred consulting costs	\$ 90,000	-
	=====	=====
Offering costs recorded in accounts payable	\$ 7,200	-
	=====	=====
Issuance of common stock in satisfaction of payable	\$ -	3,635
	=====	=====
Investment in joint venture in exchange for equipment	\$ -	132,000
	=====	=====
Issuance of note payable in exchange for accounts payable	\$ -	92,100
	=====	=====
Patent costs incurred on behalf of equity investee in exchange for receivable	\$ -	8,074
	=====	=====

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

See notes to consolidated financial statements.

F-8

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements Years Ended June 30, 2005 and 2004

1. BASIS OF PRESENTATION, BUSINESS, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

BASIS OF PRESENTATION:

The accompanying consolidated financial statements include the accounts of NanoPierce Technologies, Inc., a Nevada corporation (the Company), its wholly-owned subsidiaries, NanoPierce Connection Systems, Inc., a Nevada corporation (NCOS) which was incorporated in November 2001, ExypnoTech, LLC (ET LLC), a Colorado limited liability company, which was formed in June 2004, and through December 11, 2003, ExypnoTech, GmbH (EPT, formed in February 2002) (Note 6). Through June 30, 2004, the consolidated financial statements also included the wholly-owned foreign subsidiary, NanoPierce Card Technologies GmbH, (NCT). NCT was dissolved in June 2004, and is presented as discontinued operations (Note 3). All significant intercompany accounts and transactions have been eliminated in consolidation.

BUSINESS:

The Company was engaged in the design, development and licensing of products using its intellectual property, the PI Technology through its subsidiaries and joint venture arrangements. The PI Technology consists of patents, pending patent applications, patent applications in preparation, trade secrets, trade names, and trademarks. The Company has designated its PI Technology as the NanoPierce Connection System (NCS(TM)) and marketed the PI Technology to companies in various industries for a wide range of applications, specifically RFID applications. As discussed below, the Company made a decision to abandon its PI Technology during the year ended June 30, 2004.

Through June 30, 2005, NCOS had no operational activities. Through June 30, 2005, EPT, an equity investment, had activities primarily consisting of manufacturing inlay components used in, among other things, Smart Labels, which is a paper sheet holding a chip-containing module that is capable of memory storage and/or processing. Scimaxx Solutions, LLC, which is an equity investment (Note 6), was primarily involved in research and development and marketing functions through April 2005, at which time it ceased operations. ET LLC business activities included the marketing and sales of RFID (Radio Frequency Identification) products in North America. ET LLC had no revenues or operations through June 30, 2005.

In August 2005, the Company entered into a joint venture with Xact Resources International, Inc. ("Xact Resources"), a privately held company. The Company purchased a 50% equity interest in the joint venture, BioAgra, LLC ("BioAgra") (a Georgia limited liability company) for \$905,000 in cash (which includes the \$405,000 advanced to Xact Resources as of June 30, 2005) and a note payable of \$595,000, which was paid in full on September 15, 2005. BioAgra is to manufacture and sell a beta glucan product, YBG-2000, to be used as a replacement for hormone growth steroids and antibiotics in products such as poultry feed.

Currently, BioAgra is in the process of constructing the production line.

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

BioAgra expects to begin producing and shipping product at the beginning of 2006. As the production line is being completed, management of BioAgra is developing marketing plans for the sale and distribution of the product, marketing strategies and hiring administrative and manufacturing staff.

Additionally, the Company entered into an agreement with Arizcan Properties, Ltd. ("Arizcan") by which the Company will pay to Arizcan 20% of the cash distributions paid to the Company by and from BioAgra, until such time as Arizcan shall be paid \$800,000.

F-9

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements Years Ended June 30, 2005 and 2004

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS:

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

FAIR VALUE OF FINANCIAL INSTRUMENTS:

The fair values of the Company's cash and cash equivalents, notes receivable, accounts payable, other liabilities and notes payable approximate their carrying amounts due to the short maturities of these instruments.

CASH AND CASH EQUIVALENTS:

The Company considers all highly liquid investments with an original maturity of three months or less and money market instruments to be cash equivalents.

DEFERRED CONSULTING COSTS:

In June 2005, the Company entered into a twelve-month consulting services agreement with a third party, in which this party agreed to provide public and investor relation services and general business services for the twelve-month term of the agreement. Compensation consisted of 1,000,000 shares of the Company's restricted common stock with a market value of approximately \$90,000 (based on the closing market price of \$0.09 per share at the date the transaction was entered into). The deferred cost is being amortized on a straight-line basis over the twelve-month period from the date of the agreement. During the year ended June 30, 2005, \$7,500 was expensed.

AVAILABLE FOR SALE SECURITIES

Available for sale securities consist of 1,180 shares of common stock of Intercell International Corporation ("Intercell"). These securities are carried at estimated fair value (\$12 at June 30, 2005) based upon quoted market prices, and are included in other long-term assets in the Company's June 30, 2005 consolidated balance sheet. Unrealized gains and losses are computed on the basis of specific identification and are reported as a separate component of comprehensive income (loss), included as a separate item in shareholders' equity. The Company reported a decrease in the unrealized loss on available for sale securities of \$379 in 2005 and \$141 in 2004. At June 30, 2005, the unrealized loss on available for sale securities was \$12. Realized gains, realized losses, and declines in value, judged to be other-than-temporary, are

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

included in other income (expense). During the years ended June 30, 2005 and 2004, the Company did not sell any available for sale securities.

F-10

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements Years Ended June 30, 2005 and 2004

IMPAIRMENT OF INTELLECTUAL PROPERTY RIGHTS AND PATENT AND TRADEMARK APPLICATIONS:

During the year ended June 30, 2004, the Company had recorded intellectual property rights and patent and trademark applications. During the year ended June 30, 2004, the intellectual property was amortized using a useful life of 2.5 years, which was consistent with the remaining average patent protection period of the remaining intellectual property.

During the fourth quarter ended June 30, 2004, the Company made a decision to abandon its intellectual property rights, patents and patent applications, and trademarks. This decision was based on factors including the Company's evaluation of past and current operating results, and potential changes in the Company's business plan, which involve investigating potential acquisition candidates outside of the technology industry (Note 2). As a result of this decision, the Company recorded an impairment charge of \$608,061 in the fourth quarter ended June 30, 2004.

PROPERTY AND EQUIPMENT:

Property and equipment are stated at cost. Depreciation expense is provided by use of accelerated and straight-line methods over the estimated useful lives of the assets, which range from five to seven years.

REVENUE RECOGNITION:

Revenues from the sales of product are recognized at time of shipment. Revenues are deferred if significant future obligations are to be fulfilled or if collection is not probable. At June 30, 2005, there were no deferred revenues related to contract services in progress.

The Company grants credit, without collateral, to its customers. Management reviews trade receivables on an ongoing basis to determine if any receivables will potentially be uncollectible. The Company includes trade receivable balances that are determined to be uncollectible in an overall allowance for doubtful accounts. After all attempts to collect a receivable have failed, the receivable is written off against the allowance.

RESEARCH AND DEVELOPMENT:

The Company includes in research and development expense: payroll, facility rent, lab supplies and other expense items directly attributable to research and development. The Company does not contract its research and development work, nor does it, at this time, perform research and development work for others.

F-11

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements Years Ended June 30, 2005 and 2004

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

STOCK-BASED COMPENSATION:

Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for Stock Based Compensation, allows companies to choose whether to account for employee stock-based compensation on a fair value method, or to continue accounting for such compensation under the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (APB 25). The Company has chosen to continue to account for employee stock-based compensation using APB 25.

Had compensation cost for the Company's stock plans been determined based on fair value at the grant dates for awards under the plans consistent with the method prescribed under SFAS No. 123, the Company's net loss and net loss per share would have changed to the pro forma amounts indicated below:

	2005	2004
Net loss, as reported	\$ (997,616)	(1,558,083)
Total stock-based employee compensation expense determined under fair value based method for all awards	-	-
Net loss, pro forma	\$(997,616)	(1,558,083)
Net loss per share as reported	\$ (0.01)	(0.02)
Net loss per share pro forma	\$ (0.01)	(0.02)

No options were granted during the years ended June 30, 2005 and 2004.

FOREIGN CURRENCY TRANSLATION:

The financial statements of the Company's foreign equity investments (subsidiaries in 2004) are measured using the local currency (the Euro) as the functional currency. Assets and liabilities of the entities are translated at exchange rates as of the balance sheet date. Revenues and expenses are translated at average rates of exchange in effect during the period. The resulting cumulative translation adjustments have been recorded as a component of comprehensive income (loss), included as a separate item in shareholders' equity.

The cumulative translation adjustment was approximately \$123,000 at June 30, 2005 and 2004. In June 2004, a \$74,814 reduction of other comprehensive income to net income was recorded and recognized as a component of gain on discontinued operations as a result of the liquidation of NCT.

FOREIGN CURRENCY TRANSACTIONS:

Gains and losses from foreign currency transactions are included in net income (loss). Foreign currency transaction gains and losses were not significant during the years ended June 30, 2005 and 2004.

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Years Ended June 30, 2005 and 2004

COMPREHENSIVE INCOME (LOSS):

SFAS No. 130, Reporting Comprehensive Income, requires the reporting and display of comprehensive income and its components. SFAS No. 130 requires unrealized gains and losses on the Company's foreign currency translation adjustments to be included in comprehensive income (loss).

LOSS PER SHARE:

SFAS No. 128, Earnings per Share, requires dual presentation of basic and diluted earnings or loss per share (EPS) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.

Loss per share of common stock is computed based on the average number of common shares outstanding during the year. Stock options and warrants are not considered in the calculation, as the impact of the potential common shares (76,181,777 shares at June 30, 2005 and 77,381,777 shares at June 30, 2004) would be to decrease loss per share. Therefore, diluted loss per share is equivalent to basic loss per share.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS:

In December 2004, the Financial Accounting Standards Board ("FASB") issued SFAS No. 123(R), Share-Based Payment, which addresses the accounting for share-based payment transactions. SFAS No. 123(R) eliminates the ability to account for share-based compensation transactions using APB 25, and generally requires instead that such transactions be accounted and recognized in the statement of operations based on their fair value. SFAS No. 123(R) will be effective for public companies that file as small business issuers as of the first interim or annual reporting period that begins after December 15, 2005. The Company is currently evaluating the provisions of this standard. Depending upon the number and terms of options that may be granted in future periods, the implementation of this standard could have a significant impact on the Company's financial position and results of operations in future periods.

F-13

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

In December 2003, the FASB issued Interpretation No. 46R ("FIN 46R"), a revision to SFAS Interpretation No. 46, Consolidation of Variable Interest Entities. FIN 46R clarifies some of the provisions of FIN 46 and exempts certain entities from its requirements. FIN 46R requires a variable interest entity to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity's activities or is entitled to receive a majority of the entity's residual returns or both. FIN 46R also requires disclosures about variable interest entities that a company is not required to consolidate but in which it has a significant variable interest. FIN 46R became effective for variable interest entities or potential variable interest entities for periods ending after December 15, 2003 for public companies (other than small business issuers), and became effective by the end of the first annual reporting period ending after December 15, 2004 for companies that are small business issuers. FIN 46R did not have an impact on the Company's financial position or

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

results of operations.

2. GOING CONCERN AND MANAGEMENT'S PLANS:

The Company's financial statements for the year ended June 30, 2005 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company reported a net loss of \$997,616 for the year ended June 30, 2005, and an accumulated deficit of \$23,629,319 as of June 30, 2005. The Company did not recognize any revenues from its PI technology during the year ended June 30, 2005. The Company's subsidiary NCT was dissolved in June 2004 and in December 2003, the Company sold a controlling 51% interest in EPT. In addition, the Company has abandoned and recorded an impairment to its intellectual property.

These factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

In August 2005, the Company was able to raise \$1,535,000 through the exercise of 30,700,000 warrants with an exercise price of \$0.05 per share. The Company subsequently purchased a 50% equity investment in the BioAgra joint venture for \$905,000 (which includes the \$405,000 advanced to Xact Resources as of June 30, 2005) cash and a note payable of \$595,000, which was paid in full in September 2005. The Company also entered into an agreement with Arizcan Properties, Ltd. ("Arizcan") by which the Company will pay to Arizcan 20% of the cash distributions paid to the Company by and from BioAgra, until such time as Arizcan shall be paid \$800,000.

In September 2005, the Company executed a subscription agreement to sell shares of the Company's preferred stock with Arizcan. The sole director of Arizcan is related to a board member of Intercell. The Subscription Agreement provides for the sale of 200,000 shares of a Class A 8% cumulative and participating preferred shares with a sale's price of \$7.50 per share. The preferred shares are to be convertible into 60% of the Company's issued and outstanding post-split shares of the Company's common stock on the date of conversion.

Additionally, the Company intends to change its corporate name and most likely to institute a reverse split in connection with recent business events.

F-14

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements Years Ended June 30, 2005 and 2004

Currently, the Company does not have a revolving loan agreement with any financial institution, nor can the Company provide any assurance it will be able to enter into any such agreement in the future, or be able to raise funds through a further issuance of debt or equity in the Company.

3. DISCONTINUED OPERATIONS:

On April 1, 2003, NCT filed insolvency with the Courts of Munich, Germany. The insolvency filing was necessary in order to comply with specific German legal requirements. In June 2004, NCT completed its plan of self-liquidation, and the German court legally dissolved NCT.

At June 30, 2005, NCT has no remaining assets or liabilities. NCT's revenues for the years ended June 30, 2005 and 2004 as reported in discontinued

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

operations, were \$0. The Company recorded a \$454,882 gain on the disposal of NCT in 2004, which was primarily due to the extinguishment of NCT liabilities and gains recognized from the sales of equipment. NCT did not incur any income taxes during the periods presented.

4. RISK CONSIDERATIONS:

BUSINESS RISK:

The Company is subject to risks and uncertainties common to technology-based companies, including rapid technological change, dependence on principal products and third party technology, new product introductions and other activities of competitors, dependence on key personnel, and limited operating history.

INTERNATIONAL OPERATIONS:

The Company's foreign equity investment (EPT) operations are located in Germany. EPT transactions are conducted in currencies other than the U.S. dollar (the currency into which EPT's historical financial statements have been translated) primarily the Euro. As a result, the Company is exposed to adverse movements in foreign currency exchange rates. In addition, the Company is subject to risks including adverse developments in the foreign political and economic environment, trade barriers, managing foreign operations and potentially adverse tax consequences. There can be no assurance that any of these factors will not have a material adverse effect on the Company's financial condition or results of operations in the future.

5. NOTES AND ADVANCES RECEIVABLE:

Through June 30, 2005, the Company advanced a total of \$405,000 to Xact Resources, which was applied to the August 2005 purchase of the 50% equity interest in the joint venture, BioAgra with Xact Resources.

F-15

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements Years Ended June 30, 2005 and 2004

In December 2004, the Company loaned \$35,000 to Intercell in return for an unsecured, 7% promissory note, due in December 2005. The loan was made in order to assist Intercell in its efforts to support operations. From September 30, 2004 to March 17, 2005, Mr. Metzinger, the President and Chief Executive Officer of the Company, served as the Chief Executive Officer of Intercell. The Company's Chief Financial Officer also serves as the Chief Financial Officer of Intercell. On March 16, 2005, Intercell filed for protection under Chapter 11 of the U.S. Bankruptcy Laws. The Company does not believe that it will be able to fully collect this receivable and during the third quarter of the year ended June 30, 2005, recorded an allowance of \$35,000 in connection with the note receivable.

In November 2004, the Company loaned \$314,000 to Arizcan. In exchange for the loan, the Company received an unsecured, 7% promissory note, due on October 31, 2005. The funds were loaned to facilitate Arizcan's purchase of an option from certain of the Company's warrant holders, to initiate the exercise of certain existing warrants to purchase up to 15,700,000 shares of the Company's common stock. The warrants were initially issued as part of a January 2004 equity placement (Note 8). In June 2005, the Company received a payment of \$50,000, which included interest of \$11,442. In August 2005, Arizcan exercised its option on all 15,700,000 shares (Note 8).

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

6. INVESTMENTS IN AFFILIATES:

INVESTMENT IN EPT:

On December 11, 2003, a German entity, formed by former employees of EPT, purchased a controlling 51% equity interest in EPT in exchange for \$98,000, of which \$62,787 has been received through June 30, 2005. No gain or loss was incurred by the Company as a result of this transaction. As a result of the Company's reduced ownership interest and loss of control of EPT, the Company deconsolidated EPT as of December 11, 2003, and began accounting for its investment in EPT under the equity method of accounting at that time. Under the equity method of accounting, the carrying amount of the Company's investment in EPT (\$159,642 at June 30, 2005) is adjusted to recognize the Company's proportionate share of EPT's income (loss) each period.

F-16

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

Financial information of EPT as of June 30, 2005, and for the year ended June 30, 2005 and the period from December 11, 2003 through June 30, 2004 is as follows:

	June 30, 2005

Assets:	
Current assets(1)	\$ 302,189
Equipment	188,622

Total assets	\$ 490,811
	=====
Liabilities and members' equity:	
Current liabilities(2)	\$ 362,496
Members' equity	128,315

Total liabilities and members' equity	\$ 490,811
	=====

(1) Current assets include receivables in the amount of \$177,372 due from the 51% owner of EPT.

(2) Current liabilities include a payable of \$60,723 to the 51% owner of EPT.

	December 11, 2003
Year ended	through
June 30, 2005	June 30, 2004
-----	-----

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Revenues (1)	\$	586,480	\$	42,143
Expenses (2)		(676,222)		(144,094)
		-----		-----
Net loss	\$	(89,742)	\$	(101,951)
		=====		=====

(1) Revenues include \$570,584 and \$32,180, respectively, of sales to the 51% owner of EPT for each period presented.

(2) Expenses include \$60,723 and \$0, respectively, of charges paid to the 51% owner of EPT for each period presented.

Pro forma results of the Company's operations for the fiscal year ended June 30, 2004, assuming the deconsolidation of EPT occurred as of July 1, 2003, are as follows:

Revenues		\$ 5,809
Operating expenses		\$(1,869,029)
Net loss		\$(1,427,650)

F-17

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

INVESTMENT IN JOINT VENTURE INTEREST:

On September 15, 2003, the Company entered into a joint venture agreement with Scimaxx, LLC, an entity related to the Company in that a member of Scimaxx, LLC is a director of the Company. The name of the joint venture was Scimaxx Solutions, LLC (Scimaxx Solutions, a Colorado Limited Liability company formed in September 2003). The purpose of the joint venture was to provide the electronics industry with technical solutions to manufacturing problems based on the need for electrical connectivity.

The Company received a 50% interest in the joint venture in exchange for a contribution of NCOS equipment with a carrying value of approximately \$132,000 at September 15, 2003. The Company also granted Scimaxx Solutions a ten-year, non-exclusive, non-royalty bearing worldwide license to use the Company's intellectual property. Scimaxx, LLC was to invest \$50,000 cash, of which \$22,900 was received. The Company has a 49% voting interest in the joint venture. The Company determined that Scimaxx LLC was the controlling financial interest holder and therefore, the Company has accounted for its investment in Scimaxx Solutions as an equity method investment.

During the third quarter of the fiscal year ended June 30, 2005, the Company made the decision to impair the value of its investment in Scimaxx Solutions to \$0. In performing the quarterly assessment, management considered the operational history and status of the joint venture, combined with cash flow projections and other operating information. As a result of this decision, the Company recorded an impairment charge of \$63,544, which is included in equity losses of affiliates.

Unaudited financial information of Scimaxx Solutions as of June 30, 2005, and for the year ended June 30, 2005 and the period from September 15, 2003

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

(inception) through June 30, 2004, is as follows:

	June 30, 2005

Assets:	
Current assets	\$ 76
Equipment	70,455

Total assets	\$ 70,531
	=====
Liabilities and members' equity:	
Current liabilities	\$ 73,295
Members' equity	(2,764)

Total liabilities and members' equity	\$ 70,531
	=====

F-18

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

	Year ended June 30, 2005	September 15, 2003 through June 30, 2004
	-----	-----
Revenues	\$ 5,773	\$ 17,458
Expenses	(80,781)	(245,850)
	-----	-----
Net loss	\$ (75,008)	\$ (228,392)
	=====	=====

7. NOTES PAYABLE:

Related Parties:

In June 2005, an officer/director of the Company loaned \$41,000 to the Company in exchange for an unsecured, 5% note payable due in December 2005. In June 2005, the Company paid \$336 plus accrued interest of \$17. In August 2005, the Company paid the remaining \$40,664 plus accrued interest of \$298.

In June 2003, an officer/director of the Company loaned \$10,000 to the Company in exchange for an unsecured, 7% note payable due in December 2003. In September 2003, the same officer/director loaned the Company \$30,000 in exchange for an unsecured, 7% promissory note, due in September 2004. In January 2004, the Company paid the \$40,000 plus accrued interest of \$1,247.

In September 2003, Intercell, an affiliate of the Company at the time, loaned

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

the Company \$35,000 in exchange for an unsecured, 7% promissory note due in September 2004. In November 2003, Intercell loaned the Company \$100,000 in exchange for a 7%, promissory note due in November 2004. This promissory note was collateralized by an assignment of a 51% interest in the proceeds, if any, the Company may have received in connection with the Financing Agreement litigation (Note 9). In January 2004, the Company paid the \$135,000, plus accrued interest of \$2,493.

F-19

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements Years Ended June 30, 2005 and 2004

Other:

In June 2005, an unrelated third party loaned the Company \$150,000 in exchange for an unsecured, promissory note due in September 2005 with interest at 15% per quarter and 2,000,000 shares of the Company's restricted common stock (1,000,000 shares were issued in June 2005 and the remaining 1,000,000 shares were issued in July 2005). At the date of issuance, the common stock had a market value of \$180,000 (based on the closing market price of \$0.09 per share on the date of the transaction). The relative fair value of the common stock (\$81,718) was accounted for as a discount applied against the face amount of the note. The discount is being amortized over the term of the promissory note. The effective interest rate on this note is 54%. On June 30, 2005, the Company recognized \$2,000 of accrued interest and amortized \$7,272 of the discount as additional interest expense. On September 8, 2005, the Company paid the \$150,000, plus accrued interest of \$22,500. At that time the remaining discount of \$74,446 was fully amortized to interest expense.

On June 30, 2005, an unrelated third party loaned the Company \$25,000 in exchange for an unsecured, 8% promissory note due in December 2005 and 1,500,000 shares of the Company's restricted common stock which were issued in July 2005. At the date of issuance, the common stock had a market value of \$150,000 (based on the closing market price of \$0.10 per share on the date of the transaction). The relative fair value of the common stock (\$21,428) was accounted for as a discount against the face amount of the note. The discount is being amortized over the term of the promissory note as additional interest expense. The effective interest rate on this note is 85%. As the promissory note was issued on June 30, 2005, the Company did not recognize any interest expense. On August 8, 2005, the Company paid the \$25,000, plus accrued interest of \$208. At that time the discount of \$21,428 was fully amortized to interest expense.

In July and August 2005, unrelated parties loaned the Company a total of \$150,000 in exchange for unsecured, 8% promissory notes due in December 2005 and 6,600,000 shares of the Company's restricted common stock. The common stock had an aggregate market value of \$574,000 (based on the closing market prices which ranged from \$0.08 to \$0.09 per share at the date of the transaction). The relative fair value of the common stock (\$117,786) was accounted for as a discount applied against the face amount the promissory notes and is to be amortized over the terms of the notes. On August 8, 2005, the Company paid the \$150,000 plus accrued interest of \$1,132. At that time the discounts totaling \$117,786 were fully amortized to interest expense. The approximate effective interest rate on these notes is 79%.

F-20

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

In 2004, the Company converted vendor payables of \$92,100 into an unsecured, non-interest bearing note payable which was repaid in March 2005. This vendor along with one other vendor agreed to forgive \$52,500 of the liabilities owed, and as a result the Company recognized a gain on the extinguishment of liabilities in 2004.

8. SHAREHOLDERS' EQUITY:

COMMON STOCK:

2005 Transactions:

In November 2004, the Company issued 1,200,000 shares of common stock upon the exercise of warrants. The Company received cash proceeds of \$112,800 (net of \$7,200 of offering costs).

In June 2005, the Company issued 1,000,000 shares of its restricted common stock as consideration for a twelve-month consulting agreement. These shares of common stock had a market value of \$90,000.

In June 2005, in connection with the issuance of a \$150,000 promissory note, the Company agreed to issue 2,000,000 shares of its restricted common stock, valued at \$81,718, of which 1,000,000 shares were issued in June 2005, and 1,000,000 shares were issued in July 2005.

In June 2005, in connection with the issuance of a \$25,000 promissory note, the Company agreed to issue 1,500,000 shares of its restricted common stock, which were issued in July 2005. The shares were valued at \$21,428.

In June 2005, in connection with the Company's financing efforts, the Company committed to issuing 1,000,000 shares of its restricted common stock to an unrelated third party. The market value of the shares was \$90,000 (based on a closing market price of \$0.09 per share at the date of the transaction). The Company recognized \$90,000 of expense in June 2005 and recorded a liability of \$90,000 at June 30, 2005. The shares were issued in July 2005.

In July and August 2005, the Company issued a total of 6,600,000 shares of its restricted common stock in connection with the issuance of promissory notes totaling \$150,000. These shares were valued at \$117,786.

In August 2005, the Company issued 30,700,000 shares of its common stock in connection with the exercise of warrants for \$1,535,000 in cash. (Note 8 - Warrants).

F-21

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

2004 Transactions:

On January 20, 2004, the Company sold 20,000,000 units at a price of \$0.10 per unit for \$1.8 million in cash, pursuant to a Securities Purchase Agreement (net of \$272,000 of offering costs, discussed below). A unit consists of (i) one share of the Company's common stock, (ii) a warrant to purchase one share of common stock at an exercise price of \$0.10 per share, and (iii) a warrant to purchase two shares of the Company's common stock at an exercise price of \$0.25

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

per share. All warrants have an expiration date of January 20, 2009. As a result of the sale, the Company issued 20,000,000 shares of its common stock, warrants to purchase 20,000,000 shares of common stock at an exercise price of \$0.10 per share, and warrants to purchase 40,000,000 shares of common stock at an exercise price of \$0.25 per share.

In connection with the sale of the units, the placement agent received a fee consisting of a cash payment equal to 3% of the gross proceeds from the transaction (\$60,000) and warrants to purchase 3% of the total number of shares of common stock issued to the investors on the closing date. The Company issued to the placement agent warrants to purchase 600,000 shares of common stock with an exercise price of \$0.10 per share. The warrants expire on January 20, 2009. The placement agent is also entitled to receive an additional cash payment equal to 3% of the gross proceeds, if any, received by the Company as a result of the exercise of the \$0.10 warrants and additional warrants to purchase 3% of the total number of shares issued as a result of the exercise of the \$0.10 warrants. The Company also paid a \$200,000 finders fee to a third party (the "finder") and issued warrants to purchase 2,000,000 shares of common stock with an exercise price of \$0.10 per share. The warrants expire on January 20, 2009. This third party is also entitled to receive an additional cash payment of 10% of the gross proceeds, if any, received by the Company as a result of the exercise of the \$0.10 warrants and additional warrants to purchase 10% of the total number of shares issued as a result of the exercise of the \$0.10 warrants. The Company also incurred an additional \$12,000 of offering costs, primarily legal costs.

During the year ended June 30, 2004, the Company issued 3,850,000 shares of its common stock upon the exercise of 3,850,000 warrants, which included 1,000,000 of the warrants issued to the finder as described above. The Company received \$347,950 cash (net of \$37,050 of offering costs, of which \$11,050 is accrued at June 30, 2004) for the exercise. As described above, the Company granted to the placement agent and finder, warrants purchasing an additional 370,500 shares. The warrants are exercisable at \$0.10 per share and expire January 20, 2009. The Company also issued 185,064 of its common stock upon the cashless exercise of 403,333 warrants.

During the year ended June 30, 2004, the Company also sold 769,231 shares of restricted common stock for cash of \$100,000, and the Company issued 200,000 shares of restricted common stock in satisfaction of a \$3,635 payable.

F-22

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

STOCK OPTIONS AND WARRANTS:

Stock Options:

The Company has established two Compensatory Stock Option Plans (the "Option Plans") and has reserved 12,500,000 shares of common stock for issuance under the Option Plans. Vesting provisions are determined by the Board of Directors. All stock options expire 10 years from the date of grant.

A summary of the Option Plans is as follows:

2005	2004
-----	-----
Weighted	Weighted-

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

	Shares	average exercise price	Shares	average exercise price
	-----	-----	-----	-----
Outstanding, beginning of Year	8,787,524	\$ 1.00	8,787,524	\$ 1.00
Granted	-	-	-	-
Expired	-	-	-	-
Exercised	-	-	-	-
	-----	-----	-----	-----
Outstanding, end of year	8,787,524	\$ 1.00	8,787,524	\$ 1.00
	=====	=====	=====	=====
Options exercisable at end of year	8,637,524	\$ 1.00	8,537,524	\$ 1.00
	=====	=====	=====	=====

The following table summarizes information about stock options outstanding as of June 30, 2005:

	Options Outstanding			Options Exercisable		
	-----	-----	-----	-----	-----	-----
Range of exercise prices	Number of options	Weighted- average remaining contractual life (years)	Weighted- average exercise price	Number of options	Weighted- average exercise price	
-----	-----	-----	-----	-----	-----	-----
\$0.20 - 0.50	3,255,000	3.37	\$ 0.32	3,255,000	\$ 0.32	
0.51 - 1.00	2,495,524	7.11	0.67	2,555,524	0.64	
1.01 - 2.00	860,000	5.45	1.53	650,000	1.58	
2.01 - 3.00	2,167,000	3.74	2.28	2,167,000	2.28	
5.01 - 6.00	10,000	4.67	6.00	10,000	6.00	
	-----	-----	-----	-----	-----	-----
	8,787,524	5.67	\$ 1.00	8,637,524	\$ 1.00	
	=====	=====	=====	=====	=====	=====

F-23

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

Warrants:

At June 30, 2005, the following warrants to purchase common stock were outstanding:

Number of common shares covered by warrants	Exercise price	Expiration date
-----	-----	-----

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

20,000	\$ 1.25	August - September 2005
1,526,019	0.30 - 2.58	October - December 2005
75,000	0.30 - 0.36	January 2006
200,000	0.65	May 2006
200,000	1.25	January 2007
3,440,000	0.50 - 0.60	October - November 2007
1,333,334	0.15	April 2008
17,550,000	0.10	January 2009
40,000,000	0.15	January 2009
450,000	0.60	January 2010

64,794,353 (1)		
=====		

(1) Does not include 2,600,000 of warrants that are issuable pursuant to the securities purchase agreement described above.

No warrants were issued during the year ended June 30, 2005.

During the year ended June 30, 2005, warrants to purchase 1,200,000 shares of common stock were exercised for net cash proceeds of \$112,800 (net of commission of \$7,200).

In August 2005, warrants to purchase 30,700,000 shares of common stock were exercised for cash proceeds of \$1,535,000 in exchange for 30,700,000 shares of common stock. The proceeds were used to purchase a 50% equity interest in the BioAgra joint venture. The warrants exercise price was lowered from \$0.10 and \$0.15 per share to \$0.05 per share in connection with the exercise.

In August and September 2005, warrants to purchase 20,000 shares of common stock expired.

During the year ended June 30, 2004, warrants to purchase 3,850,000 shares of common stock were exercised for net cash proceeds of \$347,950 (net of commission of \$37,050) in exchange for 3,850,000 shares of common stock. In addition, warrants to purchase 403,333 shares of common stock were exercised on a cashless basis in exchange for 185,064 shares of common stock.

F-24

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

During the year ended June 30, 2004, warrants to purchase 732,500 shares of common stock with exercise prices ranging from \$0.30 to \$2.81 per share expired.

9. COMMITMENTS AND CONTINGENCIES

LITIGATION:

Depository Trust Suit:

In May 2004, the Company filed suit against the Depository Trust and Clearing Corporation ("DTCC"), the Depository Trust Company ("DTC"), and the National Securities Clearing Corporation ("NSCC") in the Second Judicial District Court of the County of Washoe, State of Nevada. The suit alleges multiple claims under the Nevada Revised Statutes 90.570, 90.580, 90.660 and 598A.060 and on other legal bases. The complaint alleges, among other things, that the DTCC, DTC and NSCC acted in concert to operate the "Stock Borrow

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Program," originally created to address short term delivery failures by sellers of securities in the stock market. According to the complaint, the DTCC, NSCC and DTC conspired to maintain significant open fail deliver positions of millions of shares of the Company's common stock for extended periods of time by using the Stock Borrow Program to cover these open and unsettled positions. The Company was seeking damages in the amount of \$25,000,000 and treble damages. Responsive pleadings were filed by the defendants. On April 27, 2005, the court granted a motion to dismiss the lawsuit. The Company has filed an appeal to overturn the motion to dismiss the lawsuit.

Financing Agreement Suit:

In connection with a financing obtained in October 2000, the Company filed various actions in the United States District Court for the District of Colorado against, among others, Harvest Court, LLC, Southridge Capital Investments, LLC, Daniel Pickett, Patricia Singer and Thomson Kernaghan, Ltd. for violations of federal and state securities laws, conspiracy, aiding and abetting and common law fraud among other claims. As a result of various procedural rulings, in January 2002, the United States District Court for the District of Colorado transferred the case to the United States District Court for the Southern District of New York, New York City, New York. In this litigation, Harvest Court, LLC filed counterclaims against the Company and certain officers and former board members of the Company, and a number of unrelated third parties. The counterclaims allege violations of federal securities laws and other laws. Harvest Court, LLC is seeking various forms of relief including compensatory and punitive damages. Responsive pleadings have been filed and the litigation is currently in the discovery stage.

F-25

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements Years Ended June 30, 2005 and 2004

In May 2001, Harvest Court, LLC filed suit against the Company in the Supreme Court of the State of New York, County of New York. The suit alleges that the Company breached an October 20, 2000 Stock Purchase Agreement, by not issuing 7,418,895 free trading shares of the Company's common stock in connection with the reset provisions of the Purchase Agreement due on the second reset date and approximately 4,500,225 shares due in connection with the third reset date. Harvest Court, LLC is seeking the delivery of such shares or damages in the alternative. In August 2001, the Supreme Court of the State of New York, County of New York issued a preliminary injunction ordering the Company to reserve and not transfer the shares allegedly due to Harvest Court, LLC. The Company has filed counterclaims seeking various forms of relief against Harvest Court, LLC.

The Company intends to vigorously prosecute all litigation and does not believe the outcome of the litigation will have a material adverse effect on the financial condition, results of operations or liquidity of the Company. However, it is too early at this time to determine the ultimate outcome of these matters.

Leases:

The Company has entered into certain facilities and equipment leases. The leases are non-cancelable operating leases that expire through September 30, 2006. Future minimum lease payments under these operating leases are as follows:

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

Year ending June 30, -----	Amount -----
2006	\$ 83,401
2007	14,550

	\$ 97,951
	=====

Aggregate rental expense in continuing operations under operating leases was \$113,380 and \$96,969 for the years ended June 30, 2005 and 2004, respectively.

F-26

NANOPIERCE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Years Ended June 30, 2005 and 2004

10. INCOME TAXES:

The Company and its subsidiaries did not incur income tax expense for the years ended June 30, 2005 and 2004. The reconciliation between taxes computed at the statutory federal tax rate of 34% applied to the loss from continuing operations and the effective tax rate for the years ended June 30, 2004 and 2003 is as follows:

	2005 -----	2004 -----
Expected income tax benefit	\$ (339,000)	(684,000)
Increase in valuation allowance	339,000	684,000
	-----	-----
	\$ -	-
	=====	=====

The tax effects of temporary differences that give rise to substantially all deferred tax assets at June 30, 2005 are as follows:

Deferred tax assets:	
Net operating loss	\$ 4,623,000
Intangible assets	207,000
Allowance for receivables	32,000
Less valuation allowance	(4,862,000)

Net deferred tax assets	\$ -
	=====

As of June 30, 2005, the Company has net operating loss carry forwards of approximately \$14,300,000, which expire between 2013 and 2025. The Company's net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.

Edgar Filing: NANOPIERCE TECHNOLOGIES INC - Form 10KSB

11. FOREIGN AND DOMESTIC OPERATIONS:

Operating results and long-lived assets of continuing operations as of June 30, 2005 and for the years ended June 30, 2005 and 2004, by geographic area, are presented in the table below. There were no revenues in 2005 from continuing operations and no significant amounts of transfers between geographic areas in 2005 or 2004.

	UNITED STATES -----	GERMANY -----	TOTAL -----
Revenues for year ended June 30, 2004	\$ 5,809 =====	28,449 =====	34,258 =====
Long-lived assets at June 30, 2005	\$ 15,842 =====	- =====	15,842 =====

F-27